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Abstract 
The human immunodeficiency virus type 1 (HIV-1) integrase (IN) facilitates the 
irreversible integration of the viral chromosome into the host DNA in a two-step 
reaction process consisting of 3’ end processing and strand transfer. The pre-
integration complex (PIC) is a nucleoprotein complex consisting of HIV-1 IN, 
reverse transcriptase, matrix, nucleocapsid, viral protein R (Vpr) and various 
cellular host proteins. The dominant host protein that forms part of the PIC is 
known as lens epithelium derived growth factor (LEDGF/p75) that is ubiquitously 
expressed in the nucleus. The integration of HIV-1 into chromatinised template is 
stimulated by LEDGF/p75,  while LEDGF/p75 stabilizes HIV-1 IN subunit-subunit 
interactions and promotes HIV-1 IN tetramerisation. This study aimed to identify 
and evaluate potential inhibitors of the HIV-1 IN-LEDGF/p75 interaction. A 
compound library (NCC-202) comprised of 281 compounds obtained from the 
NIH clinical collection was screened through an HIV-1 IN-LEDGF/p75 molecular 
model prepared on Accelrys Discovery StudioTM 3.1. Recombinant HIV-1 IN and 
LEDGF/p75 were expressed in bacterial cells and purified by nickel affinity and 
cation exchange chromatography, and used to establish an AlphaScreen assay 
for compound screening. A total of twelve compounds were identified as possible 
HIV-1 IN-LEDGF/p75 inhibitors. Biochemical screening using an AlphaScreen 
assay was used and a total of six of the twelve inhibitors displaying inhibition 
above 50 % were identified. The best compound with an IC50 of 1.97 µM was 
identified as lovastatin. Lovastatin was found to have an EC50 of 6.54 µM in the 
antiviral assay but activity was likely attributed to cytotoxicity with a CC50 of 5.31 
µM. Based on information from structurally similar statins, we hypothesised that a 
closed lactone ring in combination with a methyl group on the naphthalene 
structure elicited the likely inhibitory profile and that the lactone ring induced a 
large part of the cytotoxic effect of the compounds screened. Overall, we 
identified statins as potential inhibitors of the HIV-1 IN-LEDGF/p75 interaction, 
however the overlap of toxicity with antiviral effects renders statins in their current 
form unsuitable for antiretroviral treatment. 
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1.1 Introduction  
1.1.1 History of HIV 
Acquired immune  deficiency syndrome (AIDS) was first identified in 1981 in 
young, previously healthy homosexual patients, and initially described as an 
immune deficiency state that was associated with multiple microbial infections 
(Gottlieb et al., 1981). The causative agent, Human Immunodeficiency Virus 
(HIV) was initially termed Lymphadenopathy Associated Virus (LAV) due to the 
isolation of the viral agent from a lymph node biopsy of a Kinshasa patient in 
1983 (Barré-Sinoussi et al., 1983). LAV was later termed as Human T-
lymphotropic virus (HTLV)-III as the genomic structure was similar to that of 
HTLV-I (Gallo et al., 1984). In 1984 HTLV-III was determined to be the causative 
agent of AIDS and was later renamed as HIV type 1 (HIV-1) in 1986 due to the 
immune depletion it caused (Coffin, 1986; Gallo et al., 1984; Popovic et al., 
1984). In 1986 HIV-2 was isolated from commercial sex workers in west Africa 
(Marx, 1986).  
 
Historical evidence for the zoonotic origins of HIV were found in a serum sample 
stored from 1959 obtained from a male in Kinshasa, that was retrospectively 
found to be closely related to a simian immunodeficiency virus (SIV) strain that 
originated from chimpanzees of the sub species Pan Troglodytes and was 
classified as HIV-1 in 1998 (Keele et al., 2006; Zhu et al., 1998). In 1960 a lymph 
node biopsy was stored from a female in Leopoldville and was recovered recently 
(Worobey et al., 2008). The comparison of HIV-1 sequences in the 1959 sample 
and 1960 samples showed a genetic variation of 12%. This suggests that HIV-1 
was present in humans for a long time before 1960 (Worobey et al., 2008), and 
originated from multi-cross species transmissions of SIV from non-human 
primates into humans in Central and West Africa  (Sharp et al., 1994).   
 
1.1.2 Epidemiology of HIV 
HIV prevalence 
HIV/AIDS is a global pandemic with Sub-Saharan Africa more severely affected 
than any other region in the world. By the end of 2012, it was estimated that 35.3 
million people world-wide were HIV positive (Joint United Nations Program and 
United Nations, 2013). Sub Saharan Africa accounted for 66% of infections, 
followed by South and South East Asia at 12 % (Joint United Nations Programme 
on HIV/AIDS and United Nations, 2012). In 2012, 1.6 million people were newly 
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infected with HIV worldwide, a 33% improvement on 2001 statistics of 3.4 million. 
Similarly, worldwide AIDS related deaths dropped from 2.3 million in 2005 to 1.6 
million in 2012. In 2011, a total of 25 countries saw a reduction of more than 50% 
in newly infected individuals, with the Caribbean, part of Sub Saharan Africa, 
displaying a 42% reduction. North America and the Middle East saw 32 000 new 
infections in 2012. A total of 860 000 people were infected with HIV in Western 
and Central Europe whereas Australia had a lower HIV rate with a total of 35 000 
people estimated to have HIV in 2012 and only 1133 new infections in 2011.  
Progress in HIV prevention is however uneven with a rise in new infections in the 
Middle East, North Africa, Eastern Europe and Central Asia (Joint United Nations 
Programme on HIV/AIDS and United Nations, 2012). 
Nomenclature and phylogeny of HIV 
HIV strains that have been sampled from various countries indicate high genetic 
variation (Sharp et al., 2001). HIV is subdivided into two broad types HIV type 1 
(HIV-1) and HIV type 2 (HIV-2), with HIV-1 being the most prevalent (Sharp and 
Hahn, 2010). HIV-1 is most closely related to SIV found in chimpanzees (cpz) 
and gorillas while HIV-2 is related to SIV found in sooty mangabeys (smm). Thus, 
HIV types are classified based on their genetic organisation and evolutionary 
relations to their primate lentiviruses (Hirsch et al., 1989; Huet et al., 1990; Sharp 
and Hahn, 2010). Figure 1.1 shows that groups M, N and O arose from three 
independent transmissions of SIVcpz from central African chimpanzees and 
SIVsmm gave rise to HIV-2 groups A to H (Chen et al., 1997; Gao et al., 1999; 
Santiago et al., 2002). HIV-1 is divided into four lineages; groups M, N O and P. 
Group M is the main group with further subtypes of A to K, and 61 circulating 
recombinant forms (for an update see http://www.hiv.lanl.gov) (“HIV databases,” 
access date 9 January 2014.) with some evidence to suggest that the genotypic 
subtype classification may have different disease phenotypes (Shehu-Xhilaga 
and Oelrichs, 2009). Subtype B predominates in Europe, America, Japan, 
Thailand and Australia (Bobkov et al., 2004) whereas subtype C predominates in 
Southern Africa, India and Nepal (McCormack et al., 2002; Neilson et al., 1999; 
Renjifo et al., 1998; Salminen et al., 1996). Group N represents non M and non O 
as identified in 1993 in Cameroon. Group O is known as the outlier group and is 
mostly confined to West Africa. Group P was discovered most recently in 2009 
and is genetically more similar to SIV found in gorillas than the SIV in 
chimpanzees (Plantier et al., 2009). The virus was isolated from a Cameroonian 
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woman and one other human case has been identified in a Cameroonian male 
thus confirming the extremely rare circulation of group P (Vallari et al., 2011). 
  
The analysis of the occurrence of the genetic events in population history, known 
as a genetic clock, indicates that the most recent common ancestor of the HIV-1 
group M dates back to the 1920s, and the characterization of the 1959 and 1960 
samples highlights the subsequent substantial diversification of group M (Korber 
et al., 2000; Sharp and Hahn, 2010; Worobey et al., 2008; Zhu et al., 1998). 
 
Figure 1.1: Maximum likelihood phylogenetic tree analysis showing the relationships 
between HIV-1, HIV-2 and SIV partial sequences. The tree was constructed utilising pol 
gene sequence. The figure was adapted from Human Retroviruses and AIDS research, 
1999 (Korber et al., 1999).  
1.1.3 Genetic and structural organization of HIV 
Genetic organisation 
HIV has been classified in the family Retroviridae with subfamily Lentivirinae and 
the genus of Lentivirus (Chiu et al., 1985; Vogt, 1997; Wain-Hobson et al., 1985).  
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The HIV lineage is as follows: 
Viruses 
       Vertebrate Viruses 
                Retrovirus 
                      Family: Retroviridae 
                          Genus: Lentivirus 
                                 Serogroup: Primate lentivirus 
                                      Species: Human Immunodeficiency Virus 
 
The HIV genome consists of nine genes, overlapping in a number of regions, 
encoding for proteins essential to the functioning of the virus (Fauquet and 
Fargette, 2005). The genomic organisation of HIV-1 is depicted in Figure 1.2, and 
shows the nine genes encoding for structural (Gag, Pol and Env), regulatory (Tat 
and Rev) and accessory (Vif, Vpu, Vpr and Nef) proteins that make up the HIV 
virion (Gelderblom, 1991). All HIV-1 genes, gene products and associated 
functions are listed in Table 1.1.  
 
Figure 1.2: Genetic organisation of the HIV-1 genome (approximately 9.7kb), showing 
the three main structural genes gag, pol and env and regulatory (tat, rev) and accessory 
(vif, vpr, vpu, nef) genes needed for effective HIV replication. 
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Table 1.1: The gene product, size, function and location of HIV-1 structural, 
regulatory and accessory proteins. 
Gene 
product 
Size kDa Function Location 
Structural gene Products 
Gag 
MA p17 Membrane anchor, env interaction and nuclear 
transport of viral core (Foley et al., 2013) 
Virion 
CA p24 Core capsid (Foley et al., 2013) Virion 
NC p7 Nucleocaspid, binds RNA (Foley et al., 2013) Virion 
  p6 Binds VPR (Foley et al., 2013) Virion 
Pol 
Protease (PR) p15 Cleavage of Gag-pol polyprotein precursor and 
maturation (Foley et al., 2013) 
Virion 
Reverse 
transcriptase(
RT) 
RNaseH 
p66,p51 
 
p15 
RNA-dependent and DNA dependent polymerase 
activities. RNaseH activity catalyses the cleavage of 
DNA bound RNA via a hydrolytic mechanism (Foley 
et al., 2013) 
Virion 
Integrase (IN) p31 Mediates the insertion of the HIV-1 proviral cDNA 
into the genomic DNA (Foley et al., 2013) 
Virion 
Env 
Gp160 p160 Gp120 and gp41 precursor (Bernstein et al., 1995; 
Capon and Ward, 1991) 
  
Gp120 p120 CD4 and co-receptor binding (Bernstein et al., 1995; 
Capon and Ward, 1991) 
Virion 
Gp41 p41 Membrane fusion (Bernstein et al., 1995; Capon 
and Ward, 1991) 
Plasma 
membrane 
Accessory Gene Products 
Nef p25~27 Down regulates cell surface CD4 and MHC-I 
molecules. Augments virus infectivity. Modulates 
signalling pathways of cells (Sherman and Greene, 
2002; Tungaturthi et al., 2003; Yao et al., 2002; 
Zhang et al., 2001) 
Plasma 
membrane 
Vpr p10~15 Nuclear localization of the pre-integration complex 
(PIC) , inhibits cell division, arrest cells in G2 phase 
of mitosis (Montal, 2003) 
Virion, 
Nucleus 
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Vif p23 Promotes virus infectivity, inhibits APOBEC3G 
(Sheehy et al., 2003) 
Cytoplasm, 
Virion 
Vpu p17 Induces CD4 receptor degradation in the 
endoplasmic reticulum, thus enhancing budding 
(Fisher et al., 1987; Strebel et al., 1988) 
Integral 
Membrane 
Protein 
Regulatory Gene Products 
Tat p14 Regulates viral gene expression (Seelamgari et al., 
2004) 
Primarily in 
nucleolus 
Rev  p18 Nuclear transport of viral RNA, stability and 
utilization factor (Glushakova et al., 2001; 
Shaheduzzaman et al., 2002; Stoddart et al., 2003) 
Primarily in 
nucleolus 
 
Structural organisation 
The structure of HIV-1 can be described as a classical retrovirus, consisting of 
two plus strands of HIV-1 RNA (ribonucleic acid) with each containing a copy of 
the nine genes of the virus. Figure 1.3 shows the structural makeup of HIV-1 
where the RNA is enclosed in a capsid that consists of approximately two 
thousand copies of p24 viral protein (Goto et al., 1998). The capsid is then 
surrounded by the matrix (p17) which is further surrounded by a lipid bilayer 
formed from the cellular membrane of the host cell during budding of the newly 
formed virus particle, within which the viral envelope glycoproteins are 
embedded. The envelope glycoprotein subunit consists of two non-covalently 
linked membrane proteins, gp120, the external protein, and gp41, the trans 
membrane protein, which anchors the glycoprotein complex to the virion (Eckert 
and Kim, 2001). The envelope glycoprotein is the most variable part of the virus 
with gp120 divided into five highly variable regions (V) interspersed by five 
constant regions (C). 
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Figure 1.3: Representative structure of the mature HIV-1 virion showing structural and 
other proteins. Glycoproteins gp120 and gp41 together form the envelope that penetrates 
the lipid bilayer. P17 forms the matrix surrounding the capsid composed of p24 molecules 
encapsulating viral RNA, IN, PR and RT.  
1.1.4 Lifecycle of HIV 
The HIV lifecycle consists of numerous stages to successfully infect a host cell 
and replicate the HIV virion to maintain infection. The first stage in the lifecycle is 
viral entry followed by reverse transcription of viral RNA into cDNA followed by 
integration, transcription and translation of viral proteins, and finally virion 
assembly and budding (Figure 1.4).  
 
The steps in the viral lifecycle include: 
Viral entry 
HIV-1 entry follows a sequential sequence whose purpose is to deliver virus and 
requires three main steps; namely, attachment to the host cell and CD4 binding, 
co-receptor binding and membrane fusion (Mondor et al., 1998; Moulard et al., 
2000). Once the HIV-1 gp120 has bound to the CD4 receptor, it undergoes 
Literature review 
9 
 
  
Figure 1.4: Typical lifecycle of HIV-1 showing entry, reverse transcription, integration, 
transcription, translation, assembly and budding. In the first step of the HIV-1 lifecycle the 
virion attaches to the host cell via the CD4 receptor and the chemokine receptor followed 
by viral entry. Once the virion has entered the host cell the nucleocapsid is uncoated 
allowing reverse transcription to occur where the viral DNA is then transported to the 
nucleus in the form of the PIC where integration will occur. The viral DNA is irreversibly 
integrated into host DNA, viral mRNA is transcribed and transported out of the nucleus 
where proteins are translated. The proteins assemble to form new virion particles and 
bud from the surface of the host cell, releasing immature virion particles. 
 
conformational changes allowing it to bind to a co-receptor (Choe et al., 1996; 
Deng et al., 1996; Dragic et al., 1996). The most common co-receptors are 
chemokine receptors CCR5 and CXCR4 (Doranz et al., 1996; Hoffman et al., 
1998; Zhang et al., 1998). After the binding of gp120 to CD4 and the co-receptor, 
there is a conformational change in gp41 where the N-terminal is inserted into the 
target cell membrane (Eckert and Kim, 2001). This results in a fusion pore which 
allows the viral capsid to enter the cell (Chan et al., 1997; Weissenhorn et al., 
1997). Once the virus has entered the cell, the capsid is uncoated and the viral 
genome is released in preparation for reverse transcription.  
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Reverse transcription 
Two enzymes are needed for transcription, namely DNA polymerase and 
RNaseH. Both enzymes are part of reverse transcriptase. DNA polymerase can 
copy the RNA or DNA and RNaseH degrades the RNA template. The viral RNA 
genome serves as a template for provirus formation by RT. HIV-1 contains a 
primer binding site approximately 180 nucleotides from the 5’ end of the RNA that 
allows for the process of DNA synthesis (Fouchier and Malim, 1999; Gallay et al., 
1997). DNA synthesis creates an RNA-DNA complex where the RNA is first 
reverse transcribed into single stranded DNA. RNaseH degrades the RNA as 
DNA is synthesized but cannot cleave a purine rich sequence that serves as the 
primer for the second strand of DNA synthesis (Gallay et al., 1997). The second 
cDNA strand is synthesised, 3’ end processed by IN, and then forms a complex 
with proteins from both the host and virus known as the PIC (PIC; reviewed in 
more detail in section 1.3) and is actively transported to the nucleus for 
integration (Fouchier and Malim, 1999; Gallay et al., 1997).  
 
Integration, transcription and translation 
HIV-1 is either spliced and randomly integrated into the host DNA or it forms 
stable DNA circles (Bushman et al., 1990). Once the DNA is integrated into the 
host genome by strand transfer it is known as a provirus. The provirus has 
identical long terminal repeat (LTR) copies on either side of the coding region 
(Nekhai and Jeang, 2006). The 5’ LTR now functions as the promoter regulating 
the production of RNA transcripts. The RNA transcripts may now be spliced in 
preparation for translation to form viral proteins or transported out of the nucleus 
in unspliced form to form new virion particles (Nekhai and Jeang, 2006).  
 
Viral assembly and budding 
The viral protease initiates cleavage of the Gag/Pol polyprotein. Immature viral 
polypeptides and full length HIV-1 RNA transcripts are assembled on the cell 
membrane to form immature particles. The lipid membrane of the new immature 
particle is formed from the host cells plasma membrane. Vpu facilitates the virion 
release from the cell membrane (Strebel et al., 1988). During the budding 
process, viral proteins within the immature particle are processed into their 
functional forms by protease and are rearranged into the mature particles 
(Shehu-Xhilaga and Oelrichs, 2009). 
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1.1.5 Drug targets of HIV-1 and drug intervention 
Within the HIV-1 lifecycle, each of the steps described above is a potential target 
for intervention with antiretroviral therapy. Currently, antiretroviral drugs targeting 
entry, reverse transcription, integration and cleavage of the viral polyproteins by 
protease are in clinical use.  
 
The first targeted stage is viral entry, with US Food and Drug Administration 
(FDA) approved inhibitors falling into two classes, including chemokine receptor 
antagonists and fusion inhibitors. Enfuvirtide (Fuzeon, Roche Diagnostics) is a 
gp41 binder (Kilby et al., 2002; Lalezari et al., 2003), preventing the fusion of the 
viral membrane with the host membrane.  Maraviroc (Selzentry, Pfizer) binds to 
CCR5 preventing an interaction with gp120 (Lieberman-Blum et al., 2008). 
Several viral entry inhibitors are currently in clinical trials such as TNX-
355/ibalizumab, a humanised anti CD4 monoclonal antibody that binds to CD4 
and inhibits docking of the virus. PRO140 a humanised monoclonal antibody 
targeted against CCR5 has been fast tracked for approval and is currently in 
phase II clinical trials (Henrich and Kuritzkes, 2013). 
 
The second targeted step for antiretroviral treatment is reverse transcription with 
RT being the first HIV-1 enzyme to be targeted for antiretroviral drug discovery 
(Mitsuya and Broder, 1987). There are three distinct groups of RT inhibitors, first 
are nucleoside reverse transcriptase inhibitors (NRTIs), secondly non-nucleoside 
reverse transcriptase inhibitors (NNRTIs) and lastly nucleotide reverse 
transcriptase inhibitors (NtRTIs). NNRTIs bind to the non-catalytic allosteric 
pocket on the enzyme whereas NRTIs block reverse transcription by binding to 
an alternative site, thereby referred to as non-competitive inhibitors, and inhibit 
the movement of the protein domains of RT which are needed for DNA synthesis. 
NRTIs consist of lamivudine, emtricitabine, abacavir, zalcitabine, zidovudine, 
azidothymidine, stavudine. Zidovudine was the first FDA approved antiretroviral 
treatment. NNRTIs efavirenz, nevirapine, delavirdine, etravirine and rilpivirine are 
all FDA approved (Arts and Hazuda, 2012). 
Another target for intervention is assembly and maturation. Inhibitors targeting 
this step are known as protease inhibitors (PIs) and block the proteolysis of viral 
protein which is vital for the production of infectious viral particles. Protease 
inhibitors require a booster agent that does not directly reduce viral activity but 
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work as a pharmacokinetic enhancer (Wensing et al., 2010). Currently FDA 
approved PIs are saquinavir, ritonavir, indinavir, nelfinavir, amprenavir, lopinavir, 
fosaprenavir, atazanavir, tipranavir and darunavir. Ritonavir was found to have 
negative side effects at full doses such as nausea and diarrhoea, but was found 
not to have these effects at lower doses. As a result ritonavir has been used as a 
boosting agent for other PI’s (Zeldin and Petruschke, 2004). 
 
The newest form of ARVs falls under the class of IN inhibitors also known as IN 
strand transfer inhibitors (INSTIs). The current FDA approved IN inhibitors are 
raltegravir (“FDA notifications Accelerated approval for raltegravir tablets,” 2007), 
elvitegravir and dolutegravir a second generation IN inhibitor was recently 
approved by the FDA (Arts and Hazuda, 2012). New molecules are being 
designed which dually inhibit both RT and IN and are considered a type of 
‘portmanteau’ inhibitors (Abbink and Berkhout, 2008; Das and Arnold, 2013).  
Highly active antiretroviral therapy (HAART) is a highly aggressive form of 
treatment to suppress HIV-1 replication and HIV-1 disease progression. HAART 
consists of a combination of three drugs, two NRTIs and a NNRTI or PI. HAART 
was initially introduced in 1996 and has since significantly reduced the number of 
deaths worldwide. HAART prolongs lifespan of HIV-1 infected individuals by 
preventing the progression of HIV to AIDS (Bally et al., 2000). A major downfall to 
HAART is failure due to toxicity, poor response to therapy or patient non 
adherence to regimes that usually end in resistance to the drugs within the 
regime (Perelson et al., 1996). To date, these are the only FDA approved antiviral 
treatment areas. As HIV-1 is mutating and developing resistance genes to each 
of the current FDA approved drugs it is necessary to research novel areas of 
intervention. 
 
1.2 The HIV-1 integrase enzyme and integration 
The HIV IN enzyme and its cellular partners are of great interest in current drug 
discovery. 
 
1.2.1 Structure and function of HIV-1 integrase 
HIV-1 IN is responsible for the integration of viral DNA into host DNA (Coffin et 
al., 1997; Rice et al., 1996) which enables HIV to establish a permanent genetic 
reservoir. HIV-1 IN is a 32 kDa, 288 amino acid protein that is encoded by the pol 
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gene, and comprises the N-terminal domain, the catalytic core domain and the C-
terminal domain. The N-terminal domain, consisting of amino acids 1-51, 
contains an HHCC motif that binds zinc, which has been implicated in promoting  
protein multimerization (Zheng et al., 1996). The catalytic domain consisting of 
amino acids 52-219, is important in enzymatic activity of HIV-1 IN and includes 
the nuclear localization signal which is critical in mediating the import of HIV-1 IN 
in the form of the PIC (Esposito and Craigie, 1999). The third domain known as 
the C-terminal domain, consisting of amino acids 220- 288, has a DNA binding 
site and is needed for the integration reaction as it is involved in DNA-IN complex 
stabilization (Esposito and Craigie, 1998; Lodi et al., 1995). HIV-1 IN contains 
several functional domains such as the nuclear localization signal (NLS) in the N 
terminal portion of MA p17 (Bukrinsky et al., 1993; Heinzinger et al., 1994), which 
is a critical sequence mediating the import of HIV-1 IN in the form of the PIC 
(Bouyac-Bertoia et al., 2001). 
 
HIV-1 IN is functional in the multimeric form and catalyses two reactions shown in 
Figure 1.5. In the first reaction HIV-1 IN binds to the LTR at the ends of the viral 
DNA followed by the cleavage of two conserved nucleotides (CA) from the 3’ 
ends of both LTRs. This is known as 3’ processing and occurs in the cytoplasm 
as part of the PIC. The PIC is then actively transported to the nucleus where the 
resulting DNA, from 3’ processing, serves as a substrate for the integration of the 
viral DNA into the host DNA. This is a process known as strand transfer which 
occurs simultaneously at both ends of the viral DNA (Brown, 1997; Brown et al., 
1987; Craigie, 2001; Craigie et al., 1990; Engelman et al., 1991). Metal co-factors 
such as magnesium and manganese are needed for both 3’ processing and 
strand transfer. HIV-1 IN shows strong non-specific nuclease activity in the 
presence of manganese. Furthermore, sequence variations as a result of reverse 
transcription errors are better tolerated by HIV-1 IN in the presence of 
magnesium (Marchand et al., 2003).  
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Figure 1.5: Schematic representation of the HIV-1 integration reaction. i) IN in tetrameric 
form is bound to viral cDNA and generates a CA overhang during 3’ processing. ii) The 
pre- integration complex is transported to the nucleus where the strand transfer reaction 
is initiated by target DNA binding. iii) Binding is followed by nucleophilic attack and the 
formation of a phosphodiester bond leaving a 5’ DNA flap. iv) DNA is repaired by host 
machinery which results in an integrated provirus.  
 
1.3 The pre-integration complex and host factors 
1.3.1 Pre-integration complex 
The PIC is a high molecular weight nucleoprotein complex comprised of viral and 
host proteins formed within the cytoplasm (Iordanskiy et al., 2006). The exact 
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composition of the PIC is unknown but in addition to cDNA, HIV-1 IN, matrix, 
nucleocaspid, RT and VPR, the dominant host proteins included in the PIC are 
barrier to auto integration factor (BAF), High mobility group chromosomal protein 
A1 (HMGA1) and Lens Epithelial Derived Growth Factor (LEDGF) p75 with all 
components essential for efficient integration of proviral DNA (Bukrinsky et al., 
1993; Devroe et al., 2003; Gulizia et al., 1994). The viral cDNA remains 
associated with the PIC until integration is complete (Bukrinsky et al., 1992). The 
environment created by the PIC is ideal for 3’ processing as cDNA is protected 
from degradation by cellular nuclease allowing the proviral DNA to be transported 
to the nucleus in an energy dependent reaction (Sherman and Greene, 2002). 
The PIC assists in the DNA strand transfer activity by the recruitment of cellular 
cofactor LEDGF/p75. LEDGF/p75 effectively tethers HIV-1 IN to chromosomal 
DNA as can be seen in Figure 1.6. 
 
There are several residues that are involved in chemical bonds and hydrophobic 
contacts with cellular cofactors such as the LEDGF/p75 (Busschots et al., 2007; 
Cherepanov et al., 2005b; Hombrouck et al., 2007; Maertens, 2003; Rahman et 
al., 2007), HMGA1 and BAF. HMGA1 is a non-histone DNA-binding protein 
involved in the regulation of inducible gene transcription and microRNA 
expression (De Martino et al., 2009). Experimental removal of HMGA1 by gel 
filtration resulted in the loss of HIV-1 IN activity thereby indicating the essential 
need for HMGA1 for integration, once HMGA1 was added, the activity of HIV-1 IN 
was restored (Farnet and Bushman, 1997). Knockdown studies of BAF of HIV-1 
IN did not affect HIV-1 replication (Lee and Craigie, 1998), indicating that BAF is 
not essential to the replication cycle. The proof-of-concept for HMGA1 inhibitors 
is present, however; BAF research seems futile as the knockdown of BAF 
showed no effect in HIV replication. Since LEDGF/p75 was identified as a binding 
partner of HIV-1 IN, several research groups have tried to identity novel drugs 
preventing the IN-LEDGF/p75 interaction (Cherepanov, 2002). 
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Figure 1.6: Representation of the pre-integration complex of HIV-1, indicating 
LEDGF/p75 bound to HIV-1 IN at the IN binding domain (IBD) and bound to 
chromosomal DNA at the AT hook. LEDGF/p75 contains a Pro-Trp-Trp-Pro (PWWP) 
motif at the N-terminal domain needed for tight association with chromosomal DNA 
(adapted from Hare and Cherepanov, 2009).  
 
1.4 Structure and function of LEDGF/p75 
LEDGF/p75 is a hepatoma derived growth factor protein that is ubiquitously 
expressed in the nucleus of cells (Fatma et al., 2004, 2001; Hui Ge et al., 1998; 
Kubo et al., 2002; Sharma et al., 2000; Shin et al., 2008; Shinohara et al., 2002; 
Yokoyama and Cleary, 2008). LEDGF/p75 was initially discovered by micro 
sequencing of a protein that was co-purified with the general transcriptional co-
activator positive cofactor 4 (PC4) (Hui Ge et al., 1998). The following year 
LEDGF/p75 was isolated from a mouse lens epithelium library and reported to 
protect the cells from oxidative stress (Singh et al., 1999). It was thereby termed 
LEDGF (Dietz et al., 2002). LEDGF/p75 is the product of a splice variant of 
cDNA, the region codes for two proteins. The first is encoded by the 75 kDa 
species (p75) and the second variant is encoded by the smaller p52. Both 
proteins increase the activity of general transcription machinery in vitro and were 
thereby coined transcriptional co-activators p75 and p52. LEDGF/p75 and p52 
share the same N-terminal 325 amino acids but differ in the C-termini. 
LEDGF/p75 is encoded by the gene PSIP1 (Singh et al., 2000) and contains a 
nuclear localization signal (NLS) which drives nuclear localization of HIV-1 IN 
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when both proteins are produced at high levels (Llano et al., 2004; Maertens, 
2004; Vanegas et al., 2005). 
 
The C-terminus of LEDGF/p75 consists of 205 amino acids with the IBD falling in 
this region. The IBD is crucial to the proteins virological and cellular significance 
(Cherepanov et al., 2004; Vanegas et al., 2005). LEDGF/p75 serves as a bi-
functional tether, tethering chromatin at its N-terminal PWWP domain and 
tethering HIV-1 IN at the IBD on the C-terminus as seen in Figure 1.7 
(Bartholomeeusen et al., 2008, 2007; H Ge et al., 1998; Hui Ge et al., 1998; 
Llano et al., 2006b; Maertens et al., 2006; Nishizawa et al., 2001; Turlure et al., 
2006; Yokoyama and Cleary, 2008). The LEDGF/p75 interaction with HIV-1 IN 
through the IBD results in the interaction with a number of other proteins, mainly 
the cMyc interactor JPO2 (Bartholomeeusen et al., 2007; Maertens et al., 2006), 
the menin/MLL histone methyl transferase complex (Yokoyama and Cleary, 
2008) and the pogo transposable element with ZNF domain (PogZ) 
(Bartholomeeusen et al., 2008). LEDGF/p75 protects JPO2 from proteolysis and 
tethers the protein to chromatin during all phases of the cell cycle 
(Bartholomeeusen et al., 2007; Bartholomeeusen et al., 2008; Maertens et al., 
006; Yokoyama and Cleary, 2008), while the interaction with PogZ yields a tight 
chromatin bound complex during interphase but not during mitosis 
(Bartholomeeusen et al., 2008). 
 
Figure 1.7: Schematic representation of the tethering function of LEDGF/p75. 
LEDGF/p75 attaches to chromosomal DNA via the N-terminal domain of LEDGF/p75 and 
attaches to the IBD at the C-terminal domain of LEDGF/p75 thereby tethering IN to DNA. 
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1.5 HIV-1 IN-LEDGF/p75 protein-protein interaction 
Protein-protein interactions are intrinsic to every cellular process in cell based 
assays as well as in the human body. Proteins may interact with other protein or 
may interact with ligands. Interactions included in protein recognition are 
hydrogen bonding, hydrophobic interactions and electrostatic interactions. An 
understanding of these interactions is indispensable to rational drug design.  
 
Hydrogen bonding is known as non-covalent interaction were a single hydrogen 
atom is shared between two atoms. The single hydrogen is covalently linked to 
the donor atom and electrostatically linked to acceptor atom. In protein 
interactions the donor and acceptor groups are the polar amino acid side chains. 
Various studies have shown that hydrogen bonding aids in the stabilization of 
protein molecules (Habermann and Murphy, 1996; Jiang and Lai, 2002; 
Makhatadze and Privalov, 1995). 
 
Hydrophobicity is the repulsion of water from oil like substances. Hydrophobic 
interactions occur when non polar groups repel water and tend to aggregate in 
aqueous solutions due to unfavourable interactions with the water forming a 
barrier with the non-polar groups (Chandler, 2005; Matthews, 2001). In proteins, 
hydrophobic interactions drive protein folding as well as add a level of stability to 
the protein. Hydrophobic amino acids will cluster together in the core of the 
protein thereby folding and stabilizing as a result of hydrophobic interactions 
(Charton and Charton, 1982; Kauzmann, 1959). 
 
Electrostatic interactions occur between charged substances; this can be like 
charged substances causing strong attraction or oppositely charged substances 
causing strong repulsion, providing they are within 4Å of one another. On a 
protein level, electrostatic interactions occur at the carboxyl termini of the amino 
acids or at ionisable side chains of specific amino acids (Dill, 1990). The 
integration of HIV-1 into chromatinised template is stimulated by LEDGF/p75 
(Botbol et al., 2008) while LEDGF/p75 stabilizes HIV-1 IN subunit-subunit 
interactions and promotes HIV-1 IN tetramerisation (Gupta et al., 2010; McKee et 
al., 2008). 
The HIV-1 IN-LEDGF/p75 protein-protein interaction consists of p75 residues 
341-429 and the core domain of HIV-1 IN as seen in Figure 1.8 (Cherepanov et 
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al., 2005a, 2005b, 2004; Llano et al., 2004; Maertens, 2004; Vanegas et al., 
2005). The elucidation of the crystal structure of the catalytic domain of HIV-1 IN 
in a complex with the IBD demonstrates a pair of LEDGF/p75-IBD molecules 
bound at a symmetry-related position at the interface of the HIV-1 IN dimer 
(Cherepanov et al., 2005a, 2005b). LEDGF/p75 effectively tethers the viral HIV-1 
IN to the host cell chromatin through C-terminal interactions with the IBD and the 
N-terminal binding to chromatin thereby facilitating integration (Ciuffi and 
Bushman, 2006; De Rijck et al., 2010; Gijsbers et al., 2010; Marshall et al., 2007; 
Shun et al., 2007). Furthermore, LEDGF/p75 has been shown to stimulate HIV-1 
IN activity using mini HIV DNA substrates (Cherepanov, 2002). The stimulatory 
effect of LEDGF/p75 on HIV-1 IN requires LEDGF/p75 to be bound to HIV-1 IN 
prior to DNA binding, which infers that the HIV-1 IN-LEDGF/p75 interaction 
occurs before reverse transcription (Yu et al., 2007).  
 
 
Figure 1.8: Crystallographic depiction of the IN binding domain, showing (A) the overall 
ribbon structure of the CCD-IBD complex where IN chains A and B are brown and beige, 
and the IBD subunits are in purple; and (B) the key inter molecular contacts of the CCD-
IBD interface (adapted from Hare and Cherepanov, 2009)). 
  
Mutations in HIV-1 IN can cause reduced activity of the enzyme if the mutation 
lies in the IBD. HIV-1 IN mutations of A128T and E170G in the IBD render HIV-1 
IN resistant to an interaction with LEDGF/p75, further confirming the validity of 
the IBD/IN catalytic core domain function (Busschots et al., 2007; Cherepanov et 
al., 2005b). Additionally, IN mutations V165A, A179P, KR186,7AA , K159P, 
V176A and I203P cause impaired binding of host chromatin or LEDGF/p75 
binding (Xu et al., 2008; Zheng et al., 2010). The reduced affinity on HIV-1 IN 
KR186,7AA for LEDGF/p75 is due to disabled oligomerisation of HIV-1 IN 
(Berthoux et al., 2007; McKee et al., 2008). V165 is involved in the HIV-1 IN-
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LEDGF/p75 interaction interface and A179 was identified as a new amino acid in 
the LEDGF/p75 binding site critical for the IN-LEDGF/p75 interaction (Busschots, 
2004; Cherepanov et al., 2005b; Rahman et al., 2007). HIV-1 IN with mutations of 
K159P, V176A and I203P lost the ability to bind both chromatin and LEDGF/p75, 
while mutations of H171A, L172A and EH170, 1AA impaired the ability to interact 
with LEDGF/p75 but retained the ability to bind chromatin. This suggests that 
HIV-1 IN can bind chromatin independently of LEDGF/p75. Viruses harbouring 
HIV-1 IN mutants incapable of binding chromatin on LEDGF/p75 completely lost 
infectivity whereas virus harbouring HIV-1 IN mutations capable of chromatin 
binding but not LEDGF/p75 sustained low levels of HIV-1. Even in the latter case 
the level of HIV-1 infectivity was highly reduced (Zheng et al., 2010) indicating the 
importance of LEDGF/p75 to the HIV-1 integration reaction.  
 
1.6 LEDGF/p75-integrase inhibitors 
Due to the increase in mutations in HIV-1 IN against current INSTIs, focus has 
shifted to novel mechanisms of action with the design of allosteric inhibitors or 
interaction inhibitors targeting essential cofactors of integration such as the HIV-1 
IN-LEDGF/p75 interaction. Depletion of LEDGF/p75 from cells by knockout 
techniques drastically reduced HIV-1 infection in those cells (Llano et al., 2006a; 
Schrijvers et al., 2012; Shun et al., 2007; Vandekerckhove et al., 2006) providing 
proof-of-concept evidence that the HIV-1 IN-LEDGF/p75 interaction is a feasible 
target for anti HIV therapy. Various approaches have been used to design and 
identify small molecule inhibitors for the HIV-1 IN-LEDGF/p75 interaction. Most 
efforts so far have been successful with in silico screening and structurally based 
de novo design leading to the identification of HIV-1 IN-LEDGF/p75 inhibitors 
(Christ et al., 2012; De Luca et al., 2010; Du et al., 2008; Fan et al., 2011; Peat et 
al., 2012). 
 
LEDGINS are small molecules that are inhibitors of the HIV-1 IN-LEDGF/p75 
interaction and bind to the LEDGF/p75 binding site on the HIV-1 IN catalytic core 
domain, allosterically inhibiting the strand transfer activity of HIV-1 IN (Christ et 
al., 2012). This interference and inhibition suggests that LEDGINS could 
potentially block integration and therefore the replication of HIV-1 within the cell. 
LEDGINs binding may restrict IN oligomeric flexibility, affecting the formation of 
the nucleoprotein complex active in integration of viral DNA into host DNA, known 
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as the intasome. It was found that LEDGINs do stabilize HIV-1 IN and promote 
dimerization (Christ et al., 2012). This most likely restricts the multimerisation 
dynamics of HIV-1 IN needed to bind viral DNA productivity (Christ et al., 2012). 
To date there is only one HIV-1 IN-LEDGF/p75 inhibitor (BI2244336) (Gilead, 
USA) in phase I clinical studies which was recently licenced to Gilead for further 
investigations and developments (Tsiang et al., 2012). 
 
Peptides are another source of HIV-1 IN-LEDGF/p75 inhibition, however, these 
pose problems with stability and bioavailability (Adessi and Soto, 2002). Initial 
work involved peptides derived from  the LEDGF/p75 sequence that binds to HIV-
1 IN (Al-Mawsawi et al., 2008; Hayouka et al., 2010; Rhodes et al., 2011). A 
peptide was reported to compete with LEDGF/p75 for HIV-1 IN binding with an 
IC50 of 25µM. With this peptide, the strand transfer activity and 3’ processing 
inhibition was less pronounced and activity was completely lost when the DNA-IN 
complex was assembled prior to the presence of the peptide, suggesting that the 
peptide disrupts the initial DNA binding of HIV-1 IN (Hayouka et al., 2007). 
Although most work to date has focused on finding inhibitors that bind to HIV-1 IN 
to prevent LEDGF/p75 binding, Desimmie et al. recently described LEDGF/p75 
binders (Desimmie et al., 2012).  
 
It is now evident that molecules reaching high potency show a dual mechanism of 
action, actively blocking the HIV-1 IN-LEDGF/p75 interaction as well as 
displaying strand transfer inhibition (Christ et al., 2012, 2010; Kessl et al., 2012; 
Tsiang et al., 2012). Allosteric HIV-1 IN inhibitors (ALLINIs) are a new class of 
HIV-1 antiviral agents that show multimode mechanisms of action by allosterically 
modulating HIV-1 IN multimerization and interfering with HIV-1 IN-LEDGF/p75 
binding (Christ et al., 2012). ALLINI pressure has revealed an A128T substitution 
in the HIV-1 IN as a primary mechanism of resistance to IN inhibitors (Feng et al., 
2013). BI2244336 falls under a class of new agents known as non-catalytic site 
IN inhibitors (NCINIs). These compounds bind to a conserved pocket on HIV-1 IN 
that is the target for LEDGF/p75, however, this falls outside of the catalytic site 
for HIV-1 IN. Tests conducted with this compound displayed antiviral activity 
against recombinant viruses that show known HIV-1 IN inhibitor and NNRTI 
resistance. BI2244336 was found to have an EC50 of 14 nM in PhenoSense 
assays screened with 200 clinical isolates and retained its activity against 40 
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raltegravir resistant isolates with an EC50 of 26 nM (Fenwick et al., 2011; 
Simoneau et al., 2011; Yoakim et al., 2011). BI2244336 is in phase Ia clinical 
trials, being tested on healthy non HIV-1 infected individuals.  
 
Recently Hu and co-workers identified atorvastatin (Lipitor, Pfizer, USA) as an 
inhibitor of the HIV-1 IN-LEDGF/p75 interaction via molecular docking and then 
biologically determined an IC50 of 8.90 µM (Hu et al., 2012). In the same study, 
they evaluated fluvastatin (Lescol) but found this statin to be lacking notable 
inhibitory activity (Hu et al., 2012). Statins have been reported to have antiviral 
activity through clinical studies however various mechanisms of action have been 
suggested (Amet et al., 2008; del Real, 2004; Ganesan et al., 2011; Giguère and 
Tremblay, 2004; Jain and Ridker, 2005; Mazière et al., 1994). 
 
1.7 Statins 
1.7.1 Structure and function of statins 
Statins are a class of drugs that are used to lower cholesterol by the inhibition of 
the HMG-CoA reductase enzyme and are therefore known as HMG-CoA 
reductase inhibitors (Christians et al., 1998). The structural guidelines for a 
compound to be classed as a statin are a dihydroxyheptanoic acid unit and a ring 
system with different substituents as shown in Figure 1.9 (Moghadasian, 1999). 
 
 
Figure 1.9: Representative structure of the basic statin pharmocophore. 
 
Statins have been grouped into two groups based on their structure; type one 
statins have a substituted decalin-ring structure and are naturally occurring as 
seen in Figure 1.10. Statins in this class include lovastatin, simvastatin and 
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pravastatin (Istvan and Deisenhofer, 2001) and are derived from fungi Pleurotus 
ostreatus (Alarcón et al., 2003), Aspergillus terreus, (Alberts et al., 1980) and 
bacterium Nocordia autotrophica (Yoshino et al., 1986) respectively. Simvastatin 
and lovastatin are what is known as a prodrug, they are in a structurally inactive 
form when ingested but are then metabolized to their active form to inhibit HMG 
CoA reductase. Both simvastatin and lovastatin have a closed lactone ring in 
their pro-drug form and once metabolized have an open hydroxyl acid (Hamelin 
and Turgeon, 1998).  
 
Figure 1.10: Structure of type one lovastatin displaying the representative butyryl group 
of all type one statins. 
 
Type two statins are synthetic and have larger groups attached to the 
dihydroxyheptanoic acid unit as seen in Figure 1.11. The main difference 
between type one and type two is the replacement of the butyryl group of statins 
with the fluorophenyl group in type two. The fluorophenyl group has additional 
polar groups that cause a tighter bind to the HMG CoA reductase enzyme. 
Statins in this group are fluvastatin, cerivastatin, atorvastatin and rosuvastatin 
(Istvan and Deisenhofer, 2001). 
 
Figure 1.11: Atorvastatin of type two statins displaying the representative fluorophenyl 
group of all type two statins. 
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1.7.2 Antiviral activity of statins 
Statin compounds have been found to exhibit antiviral effects against HIV-1 (del 
Real, 2004; Ganesan et al., 2011; Giguère and Tremblay, 2004; Jain and Ridker, 
2005) replication of sub genomic hepatitis C virus (HCV)-1b replicons (Ikeda et 
al., 2006), suppress RNA replication of Japanese fulminant hepatitis-1 (JFH-1) 
HCV (Amemiya et al., 2008), poliovirus (Liu et al., 2006), cytomegalovirus 
(Potena et al., 2004) and respiratory syncytial virus (Gower and Graham, 2001). 
The antiviral activity of statins in HIV-1 has been shown in some in vitro studies, 
however, the exact mechanism of action is debatable (Amet et al., 2008; Giguère 
and Tremblay, 2004; Jain and Ridker, 2005; Mazière et al., 1994). The antiviral 
effect on HIV-1 has been attributed to the disruption of lipid rafts (Ganesan et al., 
2011), effects on protein prenylation and inhibition of lymphocyte function antigen 
-1 (LFA-1) and intracellular adhesion molecule-1 (ICAM-1) (del Real, 2004; 
Ganesan et al., 2011; Iyengar et al., 1998), disruption of CCR5 and RANTES 
expression levels in CD4+ T lymphocytes in vitro (Nabatov et al., 2007) and down 
regulation of RHO activity (del Real, 2004). Amet et al reported  that statins 
increase intracellular Gag and decrease virus release by HIV-1 cells (Amet et al., 
2008). The diminished geranylation, a form of prenylation, may be the principal 
mechanism of statin induced reduction of HIV-1 release (del Real, 2004). 
Conversely, groups have reported preliminary data suggesting the failure of 
statins to control in vitro and in vivo levels of HIV-1 (Moncunill et al., 2005; 
Probasco et al., 2008; Sklar et al., 2005). Moncunill and co-workers studied the 
anti HIV activity of various statin compounds but the statins showed no anti HIV-1 
activity at sub-toxic concentration. Further studies on limited exposure to statins 
showed antiviral activity of Lovastatin to levels of 3.9 µg/ml with cytotoxicity at 19 
µg/ml (Moncunill et al., 2005). Probasco and co-workers studied the effects of 
atorvastatin on anti HIV-1 activity and HIV-1 in cerebrospinal fluid in a human 
clinical pilot study, however no appreciable decrease in HIV-1 replication was 
observed (Probasco et al., 2008). Sklar and co-workers studied the effects of 
pravastatin on HIV-1 infected patients but the results showed no consistent effect 
of pravastatin on viral load (Sklar et al., 2005).   
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1.8 Techniques to analyse small molecule inhibitors of the 
LEDGF/p75-IN interaction 
1.8.1 AlphaScreen technology 
Alpha (Amplified Luminescent Proximity Homogenous Assay) technology is a 
highly flexible, no wash assay used to study protein interactions and complexes 
up to 200 nm. This bead-based assay allows the study of biological targets such 
as enzymes, receptor ligand interactions, low affinity interactions, second 
messenger levels, RNA, DNA, proteins, peptides, sugars and small molecules. 
Two bead types are needed for the assay. The first bead is a donor bead 
containing phthalcyanine, a photosensitizer that converts ambient oxygen to a 
reactive excited form of O2 upon illumination at 680 nm. The second bead, known 
as the acceptor bead, contains a thioxene derivative which allows for light 
emission. A singlet oxygen can diffuse 200 nm in solution. Once an acceptor 
bead is in a close enough proximity to the donor bead by means of protein 
association, then energy transferred from the singlet oxygen to the thioxene 
derivative results in the production of light (“AlphaScreen® for Protein-Protein 
Interaction Assays | PerkinElmer.”). Two forms of the Alpha technology are 
currently in use, namely the AlphaScreen and the AlphaLISA with the difference 
between the two assays being the acceptor beads. The thioxene derivative 
present on the acceptor bead of the AlphaScreen assay is Rubrene, which emits 
light between 520- 620 nm. In the AlphaLISA assay the acceptor beads thioxene 
derivative is Europium and emits light at 615 nm (Beaudet et al., 2008).  
 
This study focused on setting up an AlphaScreen assay to investigate the 
interaction of LEDGF/p75 and HIV-1 IN, with the aim of identifying and further 
characterization of possible inhibitors of the interaction. The proposed reagents 
for the assay include recombinant LEDGF/p75 containing a histidine tag which 
binds to the nickel chelating acceptor bead, recombinant HIV-1 IN able to bind 
biotinylated DNA capable of binding to streptavidin donor beads, as seen in 
Figure 1.12. Once the assay is optimized, it is expected that when the proteins 
interact, light is emitted between 520 nm and 620 nm, and when an inhibitor of 
interest competes or breaks the bond between LEDGF/p75 and HIV-1 IN, the 
fluorescence will drop, allowing for the determination of percentage inhibition and 
dose responses. 
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Figure 1.12: Schematic representation of the HIV-1 IN-LEDGF/p75 interaction in an 
AlphaScreen assay. The streptavidin donor bead links to the biotin labelled donor DNA-IN 
complex which then interacts with the HIS tagged LEDGF/p75 bound to the nickel 
chelating acceptor bead. 
 
1.9 Objectives 
The overall objective of this study was to identify and evaluate potential inhibitors 
of the HIV-1 IN-LEDGF/p75 interaction. This was accomplished by fulfilment of 
the following aims: 
1. Isolation and purification of recombinant LEDGF/p75 and HIV-1 IN with 
high purity and sufficient yields. 
2. Formulation of a novel biological assay to identify potential inhibitors of 
the HIV-1 IN-LEDGF/p75 interaction. 
3. Screening of compounds identified by molecular modelling using the 
newly developed AlphaScreen assay to identify potential inhibitors. 
4. In vitro screening of potential inhibitors for antiviral efficacy.  
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2.1 Reagents used in this study 
E. cloni EXPRESS® BL21 (DE3) (pLysS) and E. cloni 10G SOLOs competent 
cells (Lucigen Corporation, USA) were used in transformation with recombinant 
plasmids of pLEDGF/p75 (pFT-1-LEDGF, obtained through the NIH AIDS 
Reagent Program, Division of AIDS, NIAID, NIH: catalogue number 11396), HIV-
1 IN subtype B (IN) (pINSD.His.Sol obtained through the NIH AIDS Reagent 
Program, Division of AIDS, NIAID, NIH: catalogue number 2958), and pogo 
transposable element with zinc finger (ZNF) domain (pPogZ) (pPB-His-hPOGZ, 
Applied Biological Materials, catalogue number PV032018). The HIV-1 subtype C 
IN expressing plasmid (from isolate 05ZAFV6) was designed and available in our 
laboratory.  
 
The NCC-202 clinical collection library comprised of 281 compounds for 
repurposing was purchased from Evotec A.G (Germany). Compound structures 
were used in molecular modelling studies, and potential hit compounds were 
used in subsequent analyses. Additional statins tested for antiviral activity 
included 10mg tablets of lovastatin (Lovachol, Aspen, SA), simvastatin (Zocor, 
Merck, USA), atorvastatin (Lipitor, Pfizer, USA) and pravastatin (Pravachol, 
Aspen, SA),  mevastatin (Santa Cruz). 
 
A set of control compounds were sourced for use as positive controls in various 
assays, and included: Raltegravir (NIH AIDS Research and Reference Reagent 
Program, catalogue number 11680) for the HIV-1 IN strand transfer assay and 
antiviral assay, (2-(6-chloro-2-methyl-4-phenylquinolin-3-yl) pentanoic acid 
(CX05168) (ChemScene, USA, catalogue number CS-0685) for the AlphaScreen, 
Auronophin (Sigma Aldrich, USA) for the cytotoxicity assay, Zidovudine (NIH 
AIDS Research and Reference Reagent Program, catalogue number 3485) for 
the reverse transcriptase assay and chloramphenicol (Dulfecha Biochemie, 
Spain) for the solubility and permeability assay. All compounds were above 95% 
purity as specified by suppliers. 
 
Mammalian cell lines, MT-4 cells (antiviral and cytotoxicity testing) and HeLa 
(cytotoxicity testing), were also obtained through the NIH AIDS Reagent 
Program, Division of AIDS, NIAID, NIH: catalogue numbers 120 and 153, 
respectively. Expanded and titrated HIV-1NL4-3 was available in our laboratory. 
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2.2 Recombinant protein expression, purification and 
modification 
 
2.2.1 Protein expression of HIV-1 IN, LEDGF/p75 and PogZ 
 
2.2.1.1 Bacterial transformation 
E. cloni EXPRESS® BL21 (DE3) (pLysS) and E. cloni 10G SOLOs competent 
cells (Lucigen Corporation, USA) were each transformed with recombinant 
plasmids of pLEDGF/p75 , HIV-1 IN subtype B (IN), and pogo transposable 
element with zinc finger (ZNF) domain (pPogZ). BL21 cells were used to express 
recombinant protein, whereas 10G SOLOs were used for recombinant plasmid 
purification. The transformation protocol was followed according to 
manufacturer’s instructions. Briefly, BL21 (DE3) (pLysS) cells and 10G SOLOs 
were thawed on ice and 49 µl of cells were added to 0.1 µg of the respective 
plasmid. The cells were incubated on ice for 30 minutes and then heat shocked 
at 42°C for 45 seconds before returning to ice for two minutes. Room 
temperature recovery media (Lucigen Corporation, USA) was then added to a 
final volume of 1 ml and the mixture was vigorously shaken for one hour at 37°C. 
Luria Bertani (LB) Agar (Laboratorios Conda, Spain) plates were made containing 
the respective antibiotic; 100 µg/ml ampicillin (Melford, USA) for pLEDGF/p75 
and pINSD.His.Sol and 30 µg/ml kanamycin (Roche Diagnostics, Switzerland) for 
pPogZ. Expression bacterial plates contained 35 µg/ml chloramphenicol 
(Dulfecha Biochemie, Spain) in addition to the primary antibiotic. Room 
temperature LB agar plates were spread with 100 µl of transfected BL21 cell 
culture and the plates were then incubated overnight at 37°C (Bartholomeeusen 
et al., 2008; Jenkins et al., 1996; Vandekerckhove et al., 2006). 
 
2.2.1.2 Production of glycerol stocks 
A single colony was isolated from the LB agar plate and inoculated into 10 ml LB 
Broth (Laboratorios Conda, Spain) containing antibiotics relevant for each 
plasmid, and 35 µg/ml chloramphenicol was added for BL21 (DE3) (pLysS) 
cultures. The cultures were incubated at 37°C with vigorous shaking until the 
optical density (OD) reached 0.8 at 600 nm (xMark spectrophotometer, Bio-Rad, 
USA) for pLEDGF/p75 and 0.6 for pINSD.His.Sol and pPogZ. Aliquots at a ratio 
of 1:1 transformed bacteria and autoclaved 60% glycerol (Sigma Aldrich, USA) 
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were combined ensuring the mixture was homogeneous. Glycerol stocks were 
then stored at -80 °C for future use. 
2.2.1.3 Plasmid preparation 
The glycerol stock of the transformed 10G SOLOs was thawed on ice for five 
minutes and 20 µl was added to 10 ml LB broth containing ampicillin or 
kanamycin, dependant on the plasmid. The culture was then incubated overnight 
at 37°C with vigorous shaking. Recombinant plasmid extraction was performed 
utilising a Stratagene plasmid mini prep kit (Agilent technologies, USA) according 
to manufacturer’s protocol. Briefly, a 1.5 ml aliquot of cell culture was centrifuged 
at 3000 xg for one minute. The supernatant was discarded and 100 µl of solution 
1 (50 mM Tris HCl pH 7.5, 10 mM ethylenediaminetetraacetic acid (EDTA), 50 
ug/ml RNase A) was added to the spin cup and vortexed until the cell pellet was 
completely resuspended. Once homogeneous, 100 µl of solution 2 (0.2 M NaOH, 
1 % sodium dodecyl sulphate (SDS)) was then added and the micro tube and 
inverted several times. Lastly, 125 µl of solution 3 (chaotropic salt solution, buffer 
recipe not provided due to propriety mix belonging to Stratagene) was added and 
gently mixed. The micro tube was then centrifuged at 14000 xg for five minutes. 
The supernatant was transferred to a micro spin cup and pellet discarded. The 
micro spin cup was centrifuged at 14000 xg for 30 seconds. A volume of 750 µl of 
endonuclease wash was added to the micro spin cup and centrifuged at 14000 
xg for 30 seconds. The filter throughput was discarded and 750 µl of wash buffer 
(10 mM Tris HCl pH 7.5,100 mM NaCl, 2.5 mM EDTA) was added and the spin 
cup was centrifuged at 14000 xg for 30 seconds. The spin cup was removed and 
placed in a fresh 1.5 ml micro tube. A volume of 50 µl of elution buffer (10 mM 
Tris base pH 8, 1 mM EDTA) was added and incubated in the spin cup for 5 
minutes at room temperature. Finally the micro tube was centrifuged at 14000 xg 
for 30 seconds and the flow through was read on a NanoDrop 2000 (Thermo 
Scientific, USA) to determine purity and concentration of the extracted plasmid 
DNA. Aliquots were then stored at -80°C. 
2.2.1.4 Agarose gel electrophoresis and plasmid digest 
Purity and size of each recombinant plasmid was determined by agarose gel 
electrophoresis. A 1 % agarose gel (Sigma Aldrich, USA) was made with TBE (90 
mM Tris-HCl (Sigma Aldrich, USA), 90 mM boric acid (Sigma Aldrich, USA), 2 
mM EDTA (Sigma Aldrich, USA)) buffer, and 0.5 µl of SYBR gold (Life 
Technologies, USA) was added to the gel mix for staining purposes. The gel mix 
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was heated until homogeneous and poured into the casting set with comb 
inserted and allowed to cool for 30 minutes. Samples for each plasmid were 
prepared according to manufacturer’s instructions. Briefly 150 ng of the whole 
undigested plasmid was added to 1 µl of 6x loading buffer (Fermentas, USA) as 
sample one. The second and third sample was of a single digest with one of the 
restriction enzymes (RE) (Fermentas, USA) for each plasmid. LEDGF/p75 
plasmid was digested using RE BgllI and EcoR1; HIV-1 IN utilized BamH1 and 
Ndel. A total of 150 ng of plasmid was incubated with 16 µl of Nuclease free 
water, 2 µl of reaction buffer R (Fermentas, USA) and 1 µl of RE and mixed 
gently. The mixture was then incubated for two hours at 37°C. The final sample 
contained a double digest which consisted of 15 µl of nuclease free water, 2 µl of 
TangoTM buffer (Fermentas, USA), and 1 µl of DNA and 1 µl of each RE for the 
plasmid. The solution was mixed gently and incubated at 37°C for two hours. 
Subsequently, 2 µl of 6x loading dye (Fermentas, USA) was added to 12 µl of RE 
digested and undigested samples and loaded onto the agarose gel. A DNA 
Ladder (Fermentas, USA) was loaded as a reference. The gel was run at 80 V for 
approximately two hours and the gel was analysed using a Bio-Imaging Minibus 
Pro (DNR Bio-Imaging systems, Israel) using gel capture (DNR acquisitioning 
and imaging software) with an ultra violet (UV) plate and UV lamp to confirm the 
presence and size of the desired plasmid. 
2.2.1.5 Protein expression 
BL-21 (DE3) (pLysS) expression cells containing the plasmid were grown 
overnight at 37°C in LB broth containing appropriate antibiotics and 
chloramphenicol. Cells were then inoculated at 1:100 into LB broth and incubated 
with shaking at 37°C for pINSD.His.Sol and pPogZ to an optical density of 0.6 at 
600 nm, and 32°C for pLEDGF/p75 until reaching an optical density of 0.8-0.9 at 
600 nm. Cells were induced to express recombinant protein by the addition of 
1mM Isopropyl β-D-1-thiogalactopyranoside (IPTG) (Thermo Scientific, USA) 
final concentration and grown for a further three hours at appropriate 
temperatures. The pLEDGF/p75 culture temperature was decreased to 28°C for 
this step and samples were taken every hour to monitor expression. In addition, 
glucose (Sigma Aldrich, USA) positive and glucose negative samples were run 
simultaneously to determine if the presence of glucose prevented early 
expression before IPTG was added. Cell pellets were then harvested and frozen 
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at -80°C (Bartholomeeusen et al., 2008; Jenkins et al., 1996; Vandekerckhove et 
al., 2006). 
  
2.2.1.6 Sodium dodecyl sulphate polyacrylamide (SDS-PAGE) gel 
electrophoresis 
An electrophoresis tank was set up and filled with sodium dodecyl sulphate 
(SDS) tank buffer (25 mM Tris-HCl, 192 mM Glycine (Sigma Aldrich, USA), 0.1 % 
SDS (Sigma Aldrich, USA)). Crude samples taken at baseline and 60 minute 
intervals after induction were prepared by adding 10 µl of sample to 5 µl of 2x 
Sample buffer (Life Technologies, USA). The samples were boiled for two 
minutes and placed on ice. Samples were loaded onto a 4 - 20 % precast TGX 
gel (Bio-Rad, USA) and run at 80 V for approximately two hours. A quick stain 
solution (0.08 % coomassie brilliant blue R-250 (Thermo Scientific, USA), in 
deionised water, pH 3) and deionised water were heated on a hot plate until 
reaching 70°C. The gel was removed from the casting set and was immersed in 
the hot water with gentle shaking for five minutes. The hot water was replaced 
and this step was repeated three times. Finally the water was removed, the quick 
stain was added and the gel incubated with gentle shaking for 15 minutes. The 
gel was then rinsed with room temperature water and viewed on a Bio-Imager to 
determine if recombinant proteins at the desired resolution were present and 
over-expressed. 
 
2.2.1.7 Protein extraction 
Cell pellets from bacterial expression, (section 2.2.1.5), were thawed on ice for 30 
minutes. Thawed cells were lysed in lysis buffer A (1 M NaCl (Saarchem, SA), 25 
mM Tris-HCl pH7.4, 0.5 mM phenylmethanesulfonylfluoride (PMSF) (Thermo 
Scientific, USA), 5 mM imidazole (Sigma Aldrich, USA)) for LEDGF/p75, lysis 
buffer B (1 M NaCl, 20 mM Hepes (Life Technologies, USA) pH 7.2, 5 mM 
imidazole, 10 mM MgCl2 (Sigma Aldrich, USA), 0.25% CHAPS (Sigma Aldrich, 
USA), 1 mM PMSF) for HIV-1 IN and lysis buffer C (20 mM Tris-HCl pH7.4, 200 
mM NaCl, 0.5 mM PMSF, 5 mM imidazole) for PogZ. Cell lysates were then 
homogenised for one minute and aliquoted for sonication. Sonication was 
performed at 75 % at 0.6 cycles (Labsonic M ultrasonic processor, Sartorius, 
Germany). Each tube was sonicated for one minute for three cycles. Sonicated 
cell lysates were then centrifuged at 3200 xg for 30 minutes at 4°C. The 
supernatant was pooled and pellets were discarded. 
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2.2.1.8 Column chromatography 
Nickel affinity chromatography 
A HiTrapTM IMAC HP (GE Healthcare, UK) affinity column was connected to an 
ÄKTAprime plus (GE HealthCare, UK) and equilibrated with lysis buffer A, B or C 
as used in the extraction of the recombinant proteins from bacterial lysis. The 
supernatant was loaded onto the column and a concentration gradient was set 
from 0 % buffer A, B or C respectively to 100 % elution buffer A, B or C 
containing 200 mM imidazole over a 50 ml gradient.  
 
Collected fractions were run on an SDS PAGE gel as described in section 
2.2.1.6, to determine which fractions contained the desired protein. The SDS 
PAGE gel was viewed and fractions containing an over expressed protein at the 
size were pooled and concentrated using an Amicon ultra-filtration device with a 
10 kDa cut off (Millipore Merck, USA). The sample was then loaded onto a PD-10 
desalting column (GE Healthcare, UK) equilibrated with either HIV-1 IN storage 
buffer (1 M NaCl, 20 mM Hepes (pH 7.5), 0.1 mM EDTA, 1 mM DTT 
(dithiothreitol) (Thermo Scientific, USA), 10 % glycerol (Sigma Aldrich, USA) pH 
7.4)  or PogZ storage buffer (150 mM NaCl, 25 mM Tris-HCl, 2 mM DTT, 10% 
glycerol, pH 7.6) or buffers to be used in subsequent columns (see sections 
2.2.1.8 II below). Fractions were pooled and read on the NanoDrop 2000 to 
determine concentration. Glycerol was added to a final percentage of 10 % to 
pooled fractions and stored at -80°C. LEDGF/p75 samples needed additional 
purification steps were pooled. 
 
Ion exchange chromatography 
LEDGF/p75 samples were buffer exchanged into a sodium phosphate buffer A 
(50 mM NaH2PO4 (Saarchem, SA), pH 7.2) and pooled. An SP-Sepharose Fast 
Flow column (GE Healthcare, UK) was utilised and equilibrated with sodium 
phosphate buffer D and the pooled fractions were loaded onto the column. 
Fractions were then eluted in sodium phosphate elution buffer (50 mM NaH2PO4, 
1 M NaCl pH 7.2) over a 50 ml gradient from 0 M NaCl to 1 M NaCl. Fractions 
were collected and run on an SDS PAGE gel as previously described. 
 
Fractions containing LEDGF/p75 were pooled and concentrated using an Amicon 
ultra-filtration device with a 10 kDa cut off. The sample was then loaded onto a 
PD-10 column and buffer exchanged to a size exclusion buffer (250 mM NaCl, 25 
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mM Tris-HCl, pH 7.4, 2 mM DTT). Fractions were then read on a NanoDrop 2000 
to determine concentration. 
 
Size exclusion chromatography 
The Superdex 200 (GE HealthCare, UK) size exclusion column was equilibrated 
at 0.5 ml/min overnight with a LEDGF/p75 size exclusion buffer (150 mM NaCl, 
25 mM Tris-HCl, 2 mM DTT, 0.01% Tween 20 (Sigma Aldrich, USA), pH 7.6). 
The sample was loaded and allowed to elute on the ÄKTAprime plus (GE 
HealthCare, UK) at 0.2 ml per minute and 2.5 ml fractions were collected. 
Samples were run on an SDS-PAGE gel as previously described and the 
samples were concentrated using an Amicon ultra-filtration device with a 10 kDa 
cut off (Millipore Merck, USA). Glycerol was added to a final percentage of 10% 
to fractions to be stored at -80°C for future use. 
 
2.2.2 Validation of recombinant protein purification  
 
2.2.2.1 SDS PAGE gel to monitor protein purification 
Samples were collected at each stage of purification to monitor protein purity. 
Samples were boiled with 2X sample buffer (Bio-Rad, USA) for two minutes and 
loaded onto a 4 - 20% TGX gel (Bio-Rad, USA). The gel was run at 80 V in SDS 
tank buffer for two hours. After completion, the gel was quick stained and 
destained (section 2.2.1.6) to view the protein bands on the gel. Purity of the 
recombinant proteins was determined using Gel Quant Express Analysis 
software (DNR Bio-Imaging Technologies, Israel). 
 
2.2.2.2 Western blot 
An SDS PAGE gel for each expressed protein was transferred to a 
polyvinylidenedifluoride (PVDF) membrane utilizing an iBlot gel transfer system 
(Life Technologies, USA). Once transferred, the gel was placed in a standard 
coomasie stain (50 % methanol, 10 % acetic acid (ACE Chemical Company, 
Australia), 0.05 % Brilliant Blue R-250) to confirm transfer. The membrane was 
placed in a blocking buffer (5 % bovine serum albumin (BSA) (Sigma Aldrich, 
USA) Tris buffered saline solution containing Tween 20 (TTBS) (50 mM Tris-HCl, 
150 mM NaCl, 0.05 % Tween 20, pH 7.6) overnight. Once blocked, the 
membrane was washed 3 times for 5 minutes in TTBS with slight agitation. The 
membrane was placed into a 2000x dilution of primary antiserum to HIV-1 IN 
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(142-153) (NIH AIDS Reagent Program, catalogue number 3514); monoclonal 
mouse anti-PSIP (Abcam, UK) or monoclonal mouse anti-PogZ antibody (Abcam, 
UK) respective of the protein used made up in blocking buffer and incubated with 
slight shaking for two hours. At this point the membrane was washed three times 
for five minutes in TTBS buffer and then placed into a 20 000x dilution of 
secondary goat anti mouse antibody (Abcam, UK) made up in blocking buffer for 
90 minutes. Once complete, the membrane was washed three times for five 
minutes in TTBS and placed into a chemiluminescent substrate solution (Pierce 
Biotechnology, USA) in the dark for 15 minutes. The membrane was then viewed 
on the ChemiDoc™ MP System (Bio-Rad, USA) by exposure for one minute. 
 
2.2.3 Modifications of purified recombinant proteins  
 
2.2.3.1 6XHIS tag cleavage 
The 6XHIS tag on HIV-1 IN subtype B and C were cleaved by thrombin. Briefly, a 
benzamidine column (GE Healthcare, UK) was regenerated with three bed 
volumes of alternating high pH benzamindine buffer (0.1 M Tris-HCl, 0.5 M NaCl, 
pH 8.5) and a low pH benzamidine buffer (0.1 M sodium acetate (Sigma Aldrich, 
USA), 0.5 M NaCl, pH 4.5). The column was then re-equilibrated with five bed 
volumes of HIV-1 IN binding buffer (25 mM Hepes buffer, pH 7.5, 1 M NaCl, 1 
mM DTT and 10 % glycerol). Thrombin (Sigma Aldrich, USA) was made up in 
HIV-1 IN binding buffer with the addition of 25 mM CaCl2 (Sigma Aldrich, USA) to 
a final ratio of 123 units of thrombin per mg of protein. The protein was incubated 
in 1 ml final volume binding buffer containing 25 mM CaCl2 and thrombin for 4 
hours with slight shaking at 26°C. The sample was loaded onto the benzamidine 
column and eluted with the binding buffer. Fractions were immediately collected 
and run on a precast TGX gel (Bio-Rad, USA). The gel was stained as previously 
described to view which fractions contained the cleaved HIV-1 IN. The fractions 
containing HIV-1 IN were pooled and concentrated down with use of the Amicon 
ultra-filtration device with a 10 kDa cut off (Millipore Merck, USA) to 
approximately 1 ml. The HIV-1 IN was buffer exchanged with a PD-10 column 
into an HIV-1 IN storage buffer for future use. The thrombin on the column was 
removed with 0.05 M Glycine, pH 3.5.  
 
A 4 - 20 % precast TGX prestained gel (Bio-Rad, USA) was run with 6XHIS 
tagged HIV-1 IN and cleaved HIV-1 IN and was transferred to a PVDF membrane 
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for Western blotting as explained in section 2.2.2.2. The membrane was then 
blocked overnight with blocking buffer and subsequently incubated in a 1000x 
dilution of primary monoclonal mouse anti-HIS antibody (Abcam, UK) then into a 
5000x dilution of secondary goat anti mouse (Abcam, UK) to confirm the 6XHIS 
tag on the uncleaved protein and the absence of a tag on the cleaved protein. 
The membrane was viewed as previously described. 
 
2.2.3.2 Biotinylation of HIV-1 IN and PogZ  
HIV-1 IN and PogZ were biotinylated for use in the non DNA AlphaScreen assay. 
A biotin protein labelling kit (Roche Diagnostics, Switzerland) was utilized and 
biotinylation was performed according to the manufacturer’s protocol. Briefly 
purified HIV-1 IN and PogZ were buffer exchanged by dialysis using a 10 kDa 
molecular weight cut off (MWCO) snake skin dialysis tubing (Pierce 
Biotechnology, USA) to a 0.01 M (1X) phosphate buffered saline (PBS) solution 
pH7.4. Biotin was made up to 20 mg/ml in DMSO both supplied with the kit. A 
ratio of 1:10 was used to calculate the quantity of biotin according to the table 
supplied. A total of 10 units of biotin was incubated with 1 unit of HIV-1 IN or 
PogZ. Biotin was then added to the protein and incubated for two hours at room 
temperature with gentle agitation. The supplied G25 column (Pierce 
Biotechnology, USA) was blocked with biotin blocking buffer, supplied in the kit, 
and equilibrated with 30 ml of 1x phosphate buffered saline (PBS) (Sigma 
Aldrich, USA) buffer. The biotin-protein solution was added to the column and 
allowed to elute. Fractions were collected and read on the Nanodrop 2000 to 
determine the protein concentration. NaCl, DTT and glycerol were added and 
samples were aliquoted and stored at -80°C for future use. 
 
2.3. Theoretical, biochemical and biological screening of test 
compounds 
 
2.3.1. Theoretical screening of test compounds for HIV-1 
IN/LEDGF/p75 inhibition 
 
2.3.1.1. Molecular modelling of NCC collection 
The NCC-202 clinical collection library comprised of 281 compounds for 
repurposing was screened virtually with Accelrys Discovery StudioTM software 
package (licensed from Accelrys Inc., San Diego, CA, 2010, USA) for potential 
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binding to HIV-1 IN. The PDB code 2B4J model (IN-LEDGF/p75) was 
downloaded (http://www.rcsb.org/pdb) and LEDGF/p75 was removed from the 
HIV-1 IN-LEDGF/p75 complex and prepared by building missing loops, addition 
of hydrogen atoms, bond order assignment, and optimization of bond lengths, 
bond angels, torsion angels and non-bonded interactions. Known HIV-1 IN-
LEDGF/p75 inhibitors (27) identified by Bruno Simoneau et al consisting of 
known IC50, EC50, CC50 and Kd values were used to train the model (Simoneau et 
al., 2011). Subsequently, the 281 molecules were screened through the 
optimised and validated model and a total of twelve compounds were identified. 
These twelve compounds were sent forward for biological testing as possible 
HIV-1 IN-LEDGF/p75 inhibitors. Because lovastatin was identified as one of the 
12 potential IN-LEDGF/p75 inhibitors, additional statins were included in 
subsequent experiments. 
 
2.3.1.2. Osiris molecular property explorer 
The HIV-1 IN-LEDGF/p75 inhibitors selected by molecular modelling and statins 
were theoretically screened using Osiris Molecular Property Explorer available 
online at http://www.organic-chemistry.org/prog/peo/. The compounds were 
assessed and the water-octanol partitioning co-efficiency (cLogP), aqueous 
solubility (LogS), molecular weight, fragment based drug-likeness, overall drug 
score, tumourigenicity, mutagenicity, irritancy and possible effects on 
reproduction were determined.  
 
2.3.1.3. Lipinski’s Rule of Five 
All potential HIV-1 IN-LEDGF/p75 inhibitors selected by molecular modelling and 
statins were assessed theoretically in accordance with the four rules of Lipinski’s 
rule of five. The compounds were inspected using the Accelrys’ Discovery Studio 
3.1 package utilizing the ADMET function to determine the number of hydrogen 
bond donors and acceptors, and the Osiris molecular property explorer was used 
to determine molecular weight and the Log P values. With a total of four 
parameters and each parameter weighing equally a score out of four was 
determined.  
 
2.3.1.4 Statin property determination 
The melting point, logP, logS, physiological charge, hydrogen atom acceptor and 
donor, polar surface area, rotatable bond count, refractivity and polorisability 
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were determined for all statin compounds using ChemSpider available online at 
http://www.chemspider.com/ , Osiris Molecular Property Explorer available online 
at http://www.organic-chemistry.org/prog/peo/ and Accelrys Discovery StudioTM 
software package (licensed from Accelrys Inc., San Diego, CA, 2010, USA). 
 
2.3.2. Preparation of test compounds 
The 12 NCC-202 compounds were supplied as 10 mM stock solutions, and were 
further diluted in DMSO to the required concentrations. Lovastatin, simvastatin, 
atorvastatin and pravastatin 10 mg tablets were crushed separately in a mortar 
and pestle until finely ground. Distilled water (dH2O) was added to a volume of 30 
ml and thoroughly mixed until homogeneous. The mixture was added to an 
extraction vessel and 10 ml of methanol (Sigma Aldrich, USA) was passed 
through with slight agitation. This process was repeated three times to maximise 
the amount of compound extracted. One gram of ammonium sulphate (Sigma 
Aldrich, USA) was then added to the combined methanol to ensure no water 
residue was present and was passed through 0.22 µM filter paper. The methanol 
containing the respective compound was then placed on an evaporator to 
remove all solvent and leave the compound powder behind.   
 
A total of 10 mg of each purified compound powder was analysed by nuclear 
magnetic resonance (NMR) (400 MHz Bruker Avance Spectrometer at 298K 
equipped with a BBI 5 mm probe) and 1 mg of each purified compound was 
analysed by mass spectroscopy (Dionex Ultimate 3000 Rapid Separation LC 
system equipped with a C-18 pre-coated column and coupled to a microTOF QII 
Bruker mass spectrometer fitted with an electrospray source) to confirm purity of 
the extracted compound. Finally aliquots of 10 mg of compound were dissolved in 
DMSO (Sigma Aldrich, USA) to a volume of 1 ml for experimental use (Chaudhari 
et al., 2007; Deak et al., 2002; Önal and Sagirli, 2006), and stored at -20°C until 
used. The process was repeated several times to obtain sufficient yields for 
derivatisation. 
 
Statin derivatives were also synthesized. Lovastatin lactone was hydrolysed to 
the β-hydroxy acid form by using 52 mg of lovastatin, isolated from Lovachol 
tablets (as described in 2.3.2), and dissolving in a total of 10 ml dH2O. A total of 
0.1 ml 10 M sodium hydroxide (NaOH) (Saarchem, SA) solution was added to 
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bring the final NaOH concentration to 0.1 M and the mixture was allowed to stir 
overnight, after which the pH was adjusted to 7.5 with hydrochloric acid (HCl) 
(ACE Chemical Company, Australia). A mixture of water, acetonitrile (ACN) 
(Sigma Aldrich, USA) and ethyl acetate (Sigma Aldrich, USA) in a 1:1:1 ratio was 
used to precipitate the lovastatin β-hydroxy acid product which was then filtered 
through a 22 µM filter and dried. The final product was run on the NMR (400MHz 
Bruker Avance Spectrometer equipped with a broadband inverse (BBI) 5mm 
probe) and through mass spectroscopy (Dionex Ultimate 3000 Rapid Separation 
LC system equipped with a C-18 pre-coated column and coupled to a micrOTOF 
QII Bruker mass spectrometer fitted with an electrospray source) to confirm the 
β-hydroxy acid form and purity (Deak et al., 2002; Huang et al., 2010a; Önal and 
Sagirli, 2006). 
  
Pravastatin acid was condensed to the lactone form by taking 100 mg pravastatin 
acid, isolated from Aspen Pravachol tablets (as described in 2.3.2), and mixing 
with 5 ml ethyl acetate after which 2 µl of trifluoroacetic acid (ACE Chemical 
Company, Australia) was added to the suspension and the reaction was stirred 
overnight. The reaction was then dried and a mixture of water, ACN and ethyl 
acetate in 1:1:1 ratio was used to precipitate the product which was then filtered 
through a 22 µM filter paper, dried and run on the NMR (400MHz Bruker Avance 
Spectrometer equipped with a broadband inverse (BBI) 5mm probe) and through 
mass spectroscopy (Dionex Ultimate 3000 Rapid Separation LC system 
equipped with a C-18 pre-coated column and coupled to a micrOTOF QII Bruker 
mass spectrometer fitted with an electrospray source) to confirm pravastatin 
lactone product and purity (Deak et al., 2002; Önal and Sagirli, 2006; Tanaka and 
Terahara, 1982). Both lovastatin acid and pravastatin lactone were dissolved in 
DMSO at a concentration of 10 mg/ml and stored at -20°C for future use. 
Only compounds that were found to be above 95 % pure by means of NMR and 
mass spectroscopy were used in subsequent experiments. 
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2.3.3. Biochemical screening of HIV-1 IN-LEDGF/p75 inhibitors 
 
2.3.3.1. Development of the HIV-1 IN-LEDGF/p75 AlphaScreen assay 
 
2.3.3.1.1 Evaluation of the HIV-1 IN-LEDGF/p75 interaction by size exclusion 
chromatography  
The Superdex 200 (GE HealthCare, UK) size exclusion column was calibrated 
with size exclusion markers (GE Healthcare, UK). Both low molecular weight and 
high molecular weight markers were utilized. Proteins aprotonin (6 500 g/mol), 
ribonuclease A (13 700 g/mol), carbonic anhydrase (29 000 g/mol), ovalbumin 
(43 000 g/mol), conalbumin (75 000 g/mol), andolase (158 000 g/mol), ferritin 
(440 000 g/mol), thyroglobulin (669 000 g/mol) and blue dextran (2 000 000 
g/mol) were used to calibrate the size exclusion column and applied at a rate of 
0.5 ml per minute in a size exclusion sodium phosphate buffer (0.1 M 
NaH2PO4.H2O, 0.1 M Na2HPO4, pH7.4). The void volume of the column was 
determined with the use of blue dextran. Once markers had been eluted a 
standard curve was constructed for future use in determining the size of eluted 
proteins. 
 
The column was then equilibrated overnight in a size exclusion interaction buffer 
(150 mM NaCl, 25 mM Tris-HCl, 1 mM DTT, 1 mM MgCl2 and 0.01% Tween 20, 
pH 7.6). A total of 20 µM HIV-1 IN and 20 µM LEDGF/p75 were allowed to 
associate at room temperature for four hours with slight shaking. Thereafter the 
complex was loaded onto the column and allowed to elute over a four hour period 
at 0.5 ml/min.  
 
Western blot analyses were conducted as described in section 2.2.2.2, using a 
total of 20 µM HIV-1 IN and 20 µM LEDGF/p75 (both with the His tags attached) 
that were allowed to incubate together in a size exclusion interaction buffer for 
four hours at room temperature with slight shaking. The PVDF membrane was 
probed with a 2 000x dilution of primary monoclonal mouse anti-HIS antibody 
(Abcam, USA) and a 20 000x dilution of secondary goat anti mouse antibody 
(Abcam, USA).  
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2.3.3.1.2 HIV-1 IN-DNA-LEDGF/p75 AlphaScreen assay set-up 
An AlphaScreen assay previously described by Christ and co-workers was 
optimized for use (Christ et al., 2010). Briefly, 1.5 µM HIV-1 IN was incubated 
with 0.3 µM biotinylated donor DNA for 45 minutes at room temperature with 
gentle shaking. A total of 300 nM biotinylated HIV-1 IN-DNA was incubated with 
100 nM HIS tagged LEDGF/p75 for one hour in AlphaScreen assay buffer (150 
mM NaCl, 25 mM Tris, 2 mM MgCl2, 1 mM DTT, and 0.01% Tween 20 and 
0.02% BSA, pH 7.4) at 26°C with gentle shaking. Nickel chelating acceptor beads 
(Perkin Elmer, USA) and streptavidin donor beads (Perkin Elmer, USA) were 
added to a final concentration of 10 µg/ml and incubated at 30°C in the dark with 
gentle shaking. A final assay volume of 100 µl was used originally and later 
scaled down to 50 µl in ½ area Opti-Plates (Perkin Elmer, USA). Once incubation 
was complete the plate was read between 520-620 nm on the EnSpire® plate 
reader (Perkin Elmer, USA). Controls included; beads alone, HIV-1 IN-DNA 
alone, LEDGF/p75 alone, HIV-1 IN-DNA and LEDGF/p75 alone, each protein in 
isolation with beads alone, In addition, CX05168 which is a known HIV-1 IN-
LEDGF/p75 inhibitor was used as the control compound to validate the assay. 
Initially a single dose of 100 µM final concentration of CX05168 was incubated 
with 300 nM IN for 30 minutes at 26°C with slight shaking. Subsequently, 100 nM 
LEDGF/p75 was added and incubated for one hour at 26°C with slight shaking. 
Once incubations were completed 10 µg/ml final concentration of both acceptor 
and donor beads were added and incubated at 30°C with shaking in the dark for 
one hour, the plate was then read on the EnSpire® plate reader (Perkin Elmer, 
USA). Once the inhibition of the HIV-1 IN-LEDGF/p75 interaction was seen a 
dose response curve was determined to obtain a half maximal inhibitor 
concentration (IC50) for CX05168. A total of nine serial dilutions ranging from 0.39 
µM to 100 µM were run on the assay. The percentage inhibition for each dose 
was determined with use of the controls and plotted against the log of the 
concentration. The data obtained was plotted on a sigmoidal curve using Origin 
8.1 (Origin Lab Corporation, UK) and an IC50 dose was determined. 
 
2.3.3.1.3 HIV-1 IN-LEDGF/p75 AlphaScreen assay set-up 
A final concentration of 300 nM HIV-1 IN was incubated with 100 nM HIS tagged 
LEDGF/p75 for one hour at 26°C with gentle shaking. Nickel chelating acceptor 
beads and streptavidin donor beads were added to a final concentration of 10 
µg/ml for one hour in the dark with gentle shaking at 30°C. The plate was then 
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read on the EnSpire® plate reader (Perkin Elmer, USA) as described above. 
Both subtype B and C HIV-1 IN was run in the assay. Similarly, CX05168 was 
used as the control compound to validate the assay as described above in 
section 2.3.3.1.2. 
 
2.3.3.1.4. PogZ- LEDGF/p75 binding AlphaScreen assay set-up   
A PogZ- LEDGF/p75 binding AlphaScreen assay was set up to confirm that the 
identified potential inhibitors bound HIV-1 IN and not LEDGF/p75.  
The AlphaScreen assay was set up in ½ area Opti-Plates with PogZ replacing 
HIV-1 IN. A PogZ and LEDGF/p75 stock solution was prepared in AlphaScreen 
assay buffer and 300 nM PogZ was added to 100 nM LEDGF/p75 and allowed to 
incubate at room temperature with shaking for one hour. AlphaScreen nickel 
chelating acceptor beads and streptavidin donor beads were added to a final 
concentration of 10 µg/ml with the final assay volume of 50 µl. The plate was then 
incubated at 30°C for one hour in the dark with shaking and the plate was then 
read as previously described on the EnSpire® plate reader (Perkin Elmer, USA) 
and data was stored. 
 
2.3.3.1.5 AlphaScreen assay compound screening  
The three newly developed AlphaScreen assays was set up in the scaled down 
version of a 50 µl final volume.  
 
For the initial HIV-1 IN-DNA-LEDGF/p75 AlphaScreen assay, HIV-1 IN was 
incubated with DNA and a final concentration of 300 nM HIV-1 IN-DNA complex 
was incubated with 100 µM of each compound for 30 minutes at 26°C with slight 
shaking. Compounds tested included the NCC-202 compounds, raltegravir, 
CRX05168, lovastatin acid, pravastatin, pravastatin lactone, atorvastatin, 
simvastatin and mevastatin. Raltegravir was used as the positive control.  
 
Compounds displaying inhibition of above 50 % were subsequently rerun through 
the LEDGF/p75-IN-DNA AlphaScreen assay in ten serially diluted doses ranging 
from 0.39 µM to 200 µM to determine an IC50 for each compound. This was 
carried out in duplicate on the plate and in three separate experiments. 
Furthermore, the compounds displaying inhibition of above 50 % were also tested 
in the HIV-1 IN-LEDGF/p75 AlphaScreen assay and the PogZ- LEDGF/p75 
binding AlphaScreen assay.   
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2.3.3.1.6 HIV-1 IN strand transfer assay 
The donor DNA (Biotin 5’- ACCCTTTTAGTCAGTGTGGAAAATCTCTAGCA-3’ 
and 5’-ACTCCTAGAGATTTTCCACACTGACTAAAAG-3’) (Inqaba Biotech SA) 
was annealed by heating to 95°C for five minutes and then allowed to cooled to 
room temperature. 
A working concentration of donor DNA (0.15 µM) was made up in buffer F (10 
mM Tris-HCl, 0.1 M NaCl, pH7.2). A volume of 100 µl was added to the wells of a 
streptavidin-coated micro ELISA plate (R&D Systems, USA). The plate was 
sealed and incubated for one hour at room temperature with shaking at 50 rpm. 
The wells were aspirated and washed three times with 300µl 0.01M PBS, after 
which 1 µM recombinant HIV-1 IN prepared in buffer G (20 mM Hepes, 75 mM 
NaCl, 10 mM MgCl2, 2 µM ZnCl2 (Sigma Aldrich, USA), 10 mM MnCl2 (Sigma 
Aldrich, USA), 1% Glycerol pH 6.8) was added to each well and incubated for 30 
minutes with shaking at 50 rpm. The wells were then washed two times with 200 
µl buffer G. Compound samples were made up to 100 µM in buffer G and 10 µl 
added to each well in duplicate. The plate was then incubated at 37°C with 
shaking at 50rpm. A stock of 2.5 µM target DNA (5’-
TGACCAAGGGCTAATTCACT-3; fluorescein and 5’- 
AGTGAATTAGCCCCTTGGTCA-3’ fluorescein) (Inqaba Biotech, SA) was 
prepared and 10 µl added to each well and incubated at 37°C for one hour. The 
wells were then washed three times with 300 µl buffer H (0.03 M sodium citrate 
(Sigma Aldrich, USA), 0.3 M NaCl, pH 7.0) for 10 minutes. A working solution of 
1:10000 monoclonal anti-FITC alkaline phosphatase (Sigma Aldrich, USA) 
solution was prepared in buffer I (50 mM Tris-HCl, 150 mM NaCl, 0.05% Tween 
20, pH 7.4) and 200 µl was added to each well. The plate was then incubated for 
two hours at 25°C. Each well was then washed three times with 300 µl buffer J 
(50 mM Tris-HCl, 150 mM NaCl, pH 7.4) for 10 minutes per wash. A BluePhos 
substrate (KPL Inc, USA) was prepared according to manufactures specifications 
and 200 µl was added to each well and incubated for 30 minutes at 37°C. The 
plate was then quantified using a multi plate reader at 620 nm (xMARKTM, Bio-
Rad, USA). 
 
2.3.3.1.7 Reverse transcriptase assay 
Lovastatin was tested in a direct HIV-1 RT colorimetric assay (Roche 
Diagnostics, Switzerland). All solutions were made up according to the 
manufacturer’s specifications. The assay was performed according to 
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manufacturer’s protocol. Briefly, 4-6 ng of HIV-1 RT was added to a micro tube 
followed by 100 µM final concentration inhibitor and 20 µl of reaction buffer. Each 
micro tube was incubated at 37°C for one hour after which the samples were 
transferred to a micro plate, covered in foil and incubated for a further one hour at 
37°C. The solution was removed from the plate and wells washed five times with 
250 µl of RT wash buffer for 30 seconds. 
 
At this point 200 µl of a working dilution of anti-DIG-POD at 200 mU/ml was 
added per well, covered with foil and incubated for one hour at 37°C. The 
solution was removed and washed five times with RT wash buffer for 30 seconds. 
A final volume of 200 µl 2, 2’-azino-bis (3-ethylbenzothiazoline-6-sulphonic acid) 
(ABTS) substrate solution was added to wells for 10-25 minutes until sufficient 
colour had developed. The plate was then read at 405 nm (xMARKTM, Bio-Rad, 
USA) and data recorded. 
 
2.3.3.1.8 Solubility assay 
The aqueous solubility assay was adapted from the manufacturers protocol (E47 
Committee, 2008). Briefly, stock solutions of 10 mg/ml for each compound were 
dissolved in DMSO. A standard curve for each compound was established using 
concentrations of 500 µM, 200 µM, 50 µM, 12.5 µM and 3.125 µM. Compounds 
were then made up in filtered 80:20 (PBS pH7.4: ACN) maintaining a DMSO 
concentration of 5%. Chloramphenicol was included as the control for aqueous 
solubility. A total of 100 µl of compounds were placed into the 96 well filter plate 
(Millipore, Merck, USA) and placed onto the shaker at 300 rpm overnight at room 
temperature. The plate was then vacuum filtered into a deep well master block 
and compounds transferred to a UV-StarTM analysis plate. The spectrum of the 
compounds were analysed using the xMARKTM (Bio-Rad, USA) and a standard 
curve was prepared from the data obtained.  
 
Once the standard curve was determined compounds were made up to 200 µM 
and 100 µM samples in 100% PBS, pH 7.4 and placed into the filter plate and 
placed into the shaker at 300 rpm overnight at room temperature. The plate was 
then vacuum filtered and compounds transferred to a UV-StarTM plate. A total of 
40 µl ACN was added per sample and the compounds were quantified using the 
xMARKTM (Bio-Rad, USA) at the optimum wavelength for each compound. The 
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optimal absorbance for each compound was divided by the slope from the 
standard curve for each compound and multiplied by the dilution factor of ACN as 
shown in the formula below: 
 
Aqueous solubility = (Amax filtrate/slope) x 1.25 
 
2.3.3.1.9 Permeability assay 
The parallel artificial membrane permeability assay (PAMPA) was conducted as 
per manufacturers protocol (Avdeef et al., 2001). Briefly, the 96 well PAMPA 
plate was brought to room temperature 30 minutes prior to the assay. Original 
stock solutions of 10 mg/ml for each compound were prepared in DMSO. 
Compounds were then diluted to 100 µM in a filtered 0.01 M PBS pH7.4 solution 
keeping the DMSO concentration at 5%. Compounds were allowed to shake at 
30 rpm for 30 minutes at room temperature and then 300 µl added to the receiver 
plate. A total of 200 µl 0.01 M PBS, pH7.4 was added to the filter plate and the 
filtered plate was then slowly lowered onto the receiver plate and incubated at 
room temperature for five hours. The plates were then separated and compounds 
from both filter and receiver plate were transferred to a UV-StarTM analysis plate 
and quantified using the xMARKTM (Bio-Rad, USA). The optimum wavelength 
was used as previously determined in the solubility assay. The permeability for 
each compound was calculated using the formula below. 
 
Pe =  -ln [1-CA (t)/Ceq] 
            A*(1/VD + 1/VA)*t 
           Permeability 
R = 1-[CD (t)*VD + CA (t)*VA] / (C0 * VD) 
Mass retention (%) 
Where: C0 = Initial compound concentration in the donor well (mM); CD (t) = 
Compound concentration in donor well at time t (mM); CA (t) = Compound 
concentration in acceptor well at time t (mM); VD  = Donor well volume (300 µl); 
VA = Acceptor well volume (200µl); Ceq = [CD (t)*VD + CA(t)*VA] / (VD + VA); A = 
Filter area (0.3 cm2); t = incubation time (five hours = 18000 seconds). 
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2.3.4. Antiviral and cytotoxicity biological assays 
2.3.4.1 Cell tissue culture maintenance 
MT-4 cells (obtained through the NIH AIDS Reagent Program, Division of AIDS, 
NIAID, NIH: MT-4 catalogue number 120) were thawed from frozen stocks at a 
concentration of 1 x 107 cells per ml, in 10 ml of 20 % RPMI (Gibco, USA) (20% 
Foetal calf serum (Highveld Biologicals, SA), 100 µM Penicillin/ streptomycin (Life 
Technologies, USA), 100 µM Gentomycin (Life Technologies, USA), RPMI) 
media and placed into a 5 % CO2 incubator at 37°C. The day after thawing the 
cells were pelleted at 360 xg for 10 minutes and media removed. The cells were 
resuspended in 1 ml 20 % RPMI media. A 1:10 dilution of trypan blue (Life 
Technologies, USA) and cells were placed onto a counting slide for the countess 
cell counter (Life Technologies, USA). The cells were counted and cell viability 
and concentration was determined. Cells were seeded at 1 x 106 cells per ml to a 
total volume of 10 ml in 10 % RPMI media (10% Foetal calf serum, 100 µM 
Penicillin/ streptomycin, 100 µM Gentamycin, RPMI). A constant supply of MT-4 
cells were kept growing for experiments. 
 
HeLa cells (obtained through the NIH AIDS Reagent Program, Division of AIDS, 
NIAID, NIH: HeLa catalogue number 153) were thawed from frozen stocks at a 
concentration of 1 x 106 cells per ml, in 10 ml of 20 % DMEM (Gibco, USA) (20 % 
Foetal calf serum, 100 µM Penicillin/ streptomycin, 100 µM Gentamycin, DMEM) 
media and placed into a 5 % CO2 incubator at 37°C. The day after thawing the 
cells were pelleted at 360 xg for 10 minutes and media removed. The cells were 
resuspended in 10 % DMEM (10% Foetal calf serum, 100 µM Penicillin/ 
streptomycin, 100 µM Gentamycin, DMEM) and placed into a 5 % CO2 incubator 
at 37°C. The cells were monitored every day and once cells were 80 % confluent 
the DMEM media was aspirated off and the cells washed with 1x PBS and 
aspirated off. A total of 2 ml trypsin (Sigma Aldrich, USA) was added and cells 
were incubated for two minutes at 37°C after which 10 % DMEM solution was 
added to a total volume of 10 ml and cells were pelleted at 360 xg for 10 minutes 
and media removed. A 1:10 dilution of trypan blue (Life Technologies, USA) and 
cells were placed onto a counting slide for the countess cell counter (Life 
Technologies, USA). The cells were counted and cell viability and concentration 
was determined. Cells were seeded at 1 x 105 cells per ml to a total volume of 10 
ml in 10 % DMEM media (10 % Foetal calf serum, 100µM Penicillin/ 
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streptomycin, 100 µM Gentamycin, DMEM). A constant supply of HeLa cells 
were kept growing for experiments. 
 
2.3.4.2 Antiviral inhibition assays 
MT-4 cells (obtained through the NIH AIDS Reagent Program, Division of AIDS, 
NIAID, NIH: MT-4 catalogue number 120) were seeded the day before antiviral 
testing at 3 x 105 cells per ml. The following day the viability was checked and 2 x 
105 cells per ml were placed into a 50 ml conical tube and HIV-1NL4-3  stock added. 
The cells were spinoculated (O’Doherty et al., 2000) at 3000 xg for 90 minutes. 
Cells were subsequently washed four times with 0.01 M PBS to remove any 
unbound virus. A control set of cells were spinoculated without virus and washed 
four times with 0.01 M PBS to replicate the test cells. A total of 10 ml 10 % RPMI 
media was then added to the cells and 100µl of cells were added to each well of 
a Corning® Costar® 96-Well Cell Culture Plates (Sigma Aldrich, USA). The plate 
was placed into the 37°C, 5 % CO2 incubator to equilibrate for one hour. During 
the incubation compounds were made up in RPMI media containing 10 % heat 
inactivated FCS. The compounds were serially diluted from 100 µM to 1.56 µM. A 
total of 100 µl of compound solution was added to the wells containing cells and 
mixed to ensure they were homogeneous. The plate was placed into a 37°C, 5 % 
CO2 incubator for five days. 
 
A Biomerieux Vironostika HIV-1 Ab/Ag micro ELISA system was used to test for 
p24. All buffers were prepared according to manufacturer’s specifications and the 
manufacturer’s protocol was followed. Briefly, 145 µl of disruption buffer was 
added to each well including control wells and incubated at 37°C for one hour. A 
total volume of 5 µl of each test specimen was added to the disruption buffer and 
control samples were added. The plate was then incubated at 37°C for 60 
minutes and wells were then washed with 1x wash buffer for 30 seconds. 
Washing was repeated six times. Once washed 100 µl of 3,3',5,5'-
tetramethylbenzidine (TMB) substrate mix (1:1 ratio of TMB substrate A and B) 
was added and incubated for 5-30 minutes in the dark until sufficient colour had 
developed. The reaction was stopped by the addition of 100 µl 1 M sulphuric 
acid. The plates were then read on a multiplate reader at 450nm (xMARKTM, Bio-
Rad, USA). 
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2.3.4.3 Cellular Toxicity 
The day of cytotoxicity testing, cells were counted and seeded at 1 x 106 cells per 
ml. A total of 100 µl of cells were added to each well of a 96 well cell culture plate 
for testing. The plate was placed into the incubator to equilibrate to 37°C and 5 % 
CO2. During this time, test compounds were made up in 10% RPMI solution in a 
serial dilution from 100 µM to 1.56 µM.  A total of 100 µl compound was added to 
wells containing cells and mixed to ensure the solution was homogeneous with 
the cells. The plate was placed into the 37°C incubator for 5 days. On the 5th day 
10 µl of MTS was added and mixed. The plates were then incubated for a further 
four hours, and read at 490 nm (xMARKTM, Bio-Rad, USA.) The data analysis 
was completed on Origin 8.1 with the log value of the concentration plotted 
against the absorbance level to determine a dose curve. From the curve, a half 
maximal cytotoxicity CC50 for compounds was determined. Controls used 
included auranofin, raltegravir and CX05168. 
 
2.3.4.4 XCELLigence 
HeLa cells were seeded at 5x104 cells per well of the E plate (Roche Diagnostics, 
Switzerland) which was attached to the xCELLigence (Roche Diagnostics, 
Switzerland), and allowed to incubate overnight at 37°C and 5 % CO2 
concentration. Lovastatin was serially diluted in DMEM containing 10% FCS from 
200 µM to 1.56 µM and 100 µl was added to the wells on the E plate. Control 
wells contained only 5 x 104 cells per well in media. The cells were allowed to 
grow for four days at 37°C and 5 % CO2 concentration and underwent continuous 
evaluation for the four days. The data was then analyses using the Real Time 
Cell Analyser (RTCA) Software 1.2 (ACEA Biosciences, USA). 
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3.1 Protein expression, validation and modification 
3.1.1 Protein expression 
E. cloni EXPRESS® BL21 (DE3) (pLysS) and E. cloni 10G SOLOs competent 
cells (Lucigen Corporation, USA) were successfully transformed with plasmids 
carrying genes encoding for  pLEDGF/p75, HIV-1 IN (pINSD.His.Sol) and pogo 
transposable element with ZNF domain (pPogZ). The bacterial colonies were 
successfully grown on LB agar plates containing the required antibiotics for each 
plasmid. Colonies were evenly spread with good separation allowing selection of 
a single colony. A single colony from each plate was placed in fresh LB broth with 
appropriate antibiotics and grown overnight at 37°C for HIV-1 IN and PogZ and 
32°C for LEDGF/p75 followed by inoculation as described in section 2.2.1.2. 
Stocks were successfully produced for all plasmids transformed into E cloni BL21 
(DE3) (pLysS) expression cells and E cloni 10G solo plasmid cells for future 
production of plasmid or recombinant protein.  
 
Nucleotide sequencing of plasmid preparations of pLEDGF/p75, pINSD.His.Sol 
and pPogZ at Inqaba Biotechnical Industries (South Africa) confirmed the identity 
of the plasmids, and intact open reading frames (results not shown). 
RE digests were successfully performed on all extracted plasmids, and further 
confirmed the identity of the constructs. An example of the RE digests of 
pLEDGF/p75 is shown in Figure 3.2.  
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Figure 3.1 : Plasmid map of pFT-1-LEDGF, indicating restriction sites and their positions 
in base pairs. The following plasmid map was utilised to determine expected band sizes 
of products from restriction digest. 
pFT-1-LEDGF was derived from pRSETB (Life Technologies, USA). 
Recombinant LEDGF/p75 was amplified with BglII and EcoRI using the Pfu Ultra 
DNA polymerase (Stratagene,USA) by Vandegraaff and co-workers (Vandegraaff 
et al., 2006). Restriction enzymes BglII and EcoRI were used to excise the 
LEDGF/p75 insert. BglII was expected to cut at positions 435 and 1702. 
Therefore bands of 1267bp and 2781bp are expected. EcoRI is expected to cut 
at positions 206 and 1822. Therefore band sizes of 1616bp and 2867bp are 
expected. LEDGF/p75 is 530 amino acids and is therefore expected to be 1590 
nucleotides in length. 
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Figure 3.2: Agarose gel (1%) of pLEDGF/p75 with single and double restriction enzyme 
digests to confirm the presence of the gene insert in the vector. Lane 1, 1Kb DNA ladder 
(Fermentas, USA); Lane 2, undigested pLEDGF/p75; Lanes 3 and 4, single digest of 
pLEDGF/p75 with BgIII and EcoRI respectively; Lane 5, double digest of pLEDGF/p75 
with BgIII and EcoRI. Molecular weight, in base pairs is indicated on the left.  
 
Figure 3.2 show the agarose gel of pFT-1-LEDGF before and after restriction 
enzyme digest. Undigested plasmid can be seen in lane 2 with and 
approximation of 5000bp as expected. Lane 3 shows the digest with BglII 
showing band sizes of 2100bp and 1200bp which are within the expected sizes. 
Lane 4 shows the digest with EcoRI showing band sizes of 5000bp and 1600bp. 
The 5000bp band indicated incomplete digest and the 1600bp band was 
expected. Lane 5 shows the double digest with BglII and EcoRI confirming the 
single digest results. The LEDGF/p75 insert can be seen at 1600bp. 
3.1.1.1 Optimization of recombinant protein expression  
Studies were conducted on E. cloni expressing HIV-1 IN, LEDGF/p75 and PogZ 
to determine the optimal protein expression conditions as described in section 
2.2.1.5. For HIV-1 IN, an IPTG concentration of 1 mM was found optimal for 
protein expression induction, and three hours was found to be an optimal time 
post induction to harvest cells for protein purification. For PogZ, an IPTG 
L1         L2             L3             L4             L5 
5000bp 
2100bp 
1600bp 
1200bp 
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concentration of 1mM was found to be best for expression and three hours was 
found to be an optimal time post induction to harvest cells for protein purification. 
Similarly, LEDGF/p75 was optimally expressed after 1mM IPTG induction, and 
allowed to express for three hours. Overall, for future bulk expressions it was 
found that glucose had no valuable effect on preventing expression prior to 
induction, and thus was excluded from further experiments. Figure 3.3 depicts 
expression of LEDGF/p75 (75 kDa) in E. cloni BL21 (DE3) (PlysS) for a total of 
three hours post induction with 1mM IPTG. Similar expression patterns were 
seen for HIV-1 IN (32 kDa), and PogZ (150 kDa) (results not shown).   
 
                             
Figure  3.3: SDS PAGE gel indicating over expression of LEDGF/p75 after induction with 
1mM IPTG. Lane 1, precision plus protein molecular weight marker (Bio-Rad, USA); Lane 
2, uninduced culture; Lane 3, 1 hour post induction with IPTG; Lane 4, 2 hours post 
induction with IPTG; and Lane 5, three hours post induction with IPTG. Arrow indicated 
the expressed LEDGF/p75. Molecular weight, in kilo Daltons (kDa), is indicated on the 
left. The above two figures are from the same gel but have been separated for clarity. 
 
3.1.1.3 Column chromatography 
Proteins expressed during pLEDGF/p75 expression were eluted with a buffer 
containing a 200 mM imidazole concentration over a 50 ml gradient. Protein 
fractions at 14 ml through to 22 ml were run on a SDS PAGE gel (Figure 3.4). 
Fractions from the peaks containing an over expressed protein at 75 kDa for 
LEDGF/p75 were pooled and underwent ultrafiltration thereby concentrating the 
proteins.  
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Similarly, over expressed proteins at 32 kDa for HIV-1 IN and 100 kDa for PogZ 
were pooled and concentrated. In the case of HIV-1 IN, purity was observed after 
the ultrafiltration step, and was thus buffer exchanged into the IN storage buffer.  
 
Figure 3.4: Representative elution chromatogram of HiTrap Nickel affinity 
chromatography used to purify recombinant LEDGF/p75.  The blue line indicates the 
absorbance of each eluted fraction whereas the green line denotes the imidazole 
concentration gradient. The elution profile was obtained from the ÄKTAprime view 
software. Proteins were eluted at a flow rate of 1 ml per minute and collected in 2 ml 
fractions. The absorbance increases sharply at fraction 19 ml (as indicated by an arrow) 
denoting the elution of a HIS tagged protein. 
 
However, LEDGF/p75 and PogZ required further purification as contaminating 
bands were visible. LEDGF/p75 was buffer exchanged to a sodium phosphate 
buffer and loaded onto a SP-Sepharose fast flow column (GE Healthcare, UK) 
that was attached to the ÄKTAprime plus. Proteins containing a negative charge 
were then eluted by an increase in the salt concentration to 1 M and eluting over 
a 50 ml gradient. The LEDGF/p75 SP-Sepharose elution profile can be seen in 
Figure 3.5.  
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Figure 3.5: Representative elution profile of SP-Sepharose cation exchange 
chromatography used to purify LEDGF/p75. The blue line indicates the absorbance of 
each eluted fraction whereas the green line denotes salt concentration gradient. The 
elution profile was obtained using the AKTA prime view software. Proteins were eluted at 
a flow rate of 1 ml per minute and collected in 2 ml fractions. The absorbance increases 
sharply at 20 minutes denoting the elution of a negatively charged protein indicated by 
the arrow. Fractions collected between elution times of 16 to 26 minutes were run on an 
SDS PAGE gel. 
 
Fractions 8 to 13 (correlating to 16 and 26 minutes; Figure 3.5) were run on a 
SDS PAGE gel alongside a protein molecular weight marker to determine the 
presence and purity of the protein of interest (data not shown). Fractions 
containing an over expressed protein at 75 kDa, were pooled and concentrated. 
Subsequently, concentrated protein was buffer exchanged into the LEDGF/p75 
size exclusion buffer and loaded onto a Superdex 200 with use of the ÄKTAprime 
plus at a flow rate of 0.5 ml/min. The LEDGF/p75 Superdex 200 elution profile 
can be seen in Figure 3.6. Fractions 7 through to 11, correlating to 30 to 45 
minute elution times, proved to be the 75 kDa LEDGF/p75. 
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Figure 3.6: Representative elution profile of Superdex 200 size exclusion 
chromatography used to purify LEDGF/p75. The blue line indicates the absorbance of 
each eluted protein. The elution profile was obtained from the AKTA prime view software. 
Proteins were eluted at a flow rate of 0.5ml per minute and collected in 2 ml fractions. 
Fractions from each peak were run on a SDS PAGE gel. 
 
Affinity purified PogZ was buffer exchanged into a size exclusion buffer and 
loaded onto Superdex 200 with use of the ÄKTAprime plus at a flow rate of 0.5 
ml/min. Relevant PogZ containing fractions were pooled and concentrated 
(results not shown).   
 
Samples at each stage of purification for each of the three recombinant proteins 
were run on SDS PAGE gels (Figures 3.7 to 3.9) and confirm the increased purity 
with each purification step.  Purity of each sample as shown in the figure below 
was determined by using Gel Quant express (DNR Bio-Imaging technologies, 
Israel) software. Overall, purity of LEDGF/p75 increased from 44 % after affinity 
chromatography to 68 % after ion exchange chromatography to a final purity of 
over 95 % after size exclusion chromatography (Figure 3.7). HIV-1 IN was 
purified to 77 % after affinity chromatography to a final purity of 88 % after 
ultrafiltration (Figure 3.8). PogZ purity increased from 30 % after affinity 
chromatography to a final purity of 80 % by size exclusion chromatography 
(Figure 3.9), attributed to the presence of two additional bands, which despite 
further purification attempts could not be removed. 
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Figure 3.7: LEDGF/p75 SDS-PAGE gel analysis depicting purification. Lane 1, precision 
plus protein molecular weight marker (Bio-Rad, USA); Lane 2, supernatant prior to 
loading onto a Hi trap nickel affinity chromatography; Lane 3, sonicated pellet 
supernatant; Lane 4, concentrated fractions after Hi Trap nickel affinity chromatography; 
Lane 5, concentrated fractions after SP-Sepharose chromatography; and Lane 6, 
concentrated fractions from Superdex 200 size exclusion chromatography. The arrow 
indicates the 75 kDa protein of LEDGF/p75. 
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Figure 3.8: SDS-PAGE gel analysis depicting purification of HIV-1 IN. Lane 1, precision 
plus protein molecular weight marker (Bio-Rad, USA); Lane 2, sonicated pellet 
supernatant; Lane 3 sonicated cell pellet fraction; Lane 4, nickel affinity chromatography 
purified HIV-1 IN; Lane 5, concentrated HIV-1 IN; Lane 6, positive control HIV-1 IN (NIH 
AIDS Research and Reference Reagent Program). Recombinant IN at 32 kDa is denoted 
by the arrow. 
 
 
Figure 3.9: SDS PAGE gel depicting purification steps of PogZ. Lane 1, precision plus 
protein molecular weight marker (Bio-Rad, USA); Lane 2, sonicated pellet supernatant; 
Lane 3, nickel affinity chromatography purified PogZ; lane 4, Purified PogZ after size 
exclusion chromatography. 
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3.1.2 Validation of recombinant protein expression 
3.1.2.1 Western blots 
Western blots were run for each protein to confirm the expression of the desired 
protein. Purified recombinant LEDGF/p75 was run alongside an uniduced 
LEDGF/p75 bacterial culture fraction lacking a protein at 75 kDa and a Super 
Western C marker (Bio-Rad, USA). The Western blot displayed an absence of 
bands in the negative control lane and the presence of a 75 kDa band in lane 3, 
confirming the expression of LEDGF/p75 (Figure 3.10). 
 
Similarly, bands were detected for the positive control recombinant HIV-1 IN and 
the newly purified recombinant HIV-1 IN (Figure 3.11, lanes 3 and 4, 
respectively), and recombinant PogZ at 100 kDa (Figure 3.12).  
 
 
Figure 3.10: Western blot analysis confirming the expression of LEDGF/p75 with primary 
antibody anti-PSIP1. Lane 1, Super Western C marker (Bio-Rad, USA); Lane 2, negative 
control fraction from size exclusion chromatography; Lane 3, concentrated size exclusion 
chromatography purified LEDGF/p75. 
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Figure 3.11: Western blot analysis confirming expression of recombinant HIV-1 IN. Lane 
1, Super Western C marker (Bio-Rad, USA); Lane 2, negative control fraction from nickel 
affinity chromatography; Lane 3, positive control recombinant HIV-1 IN obtained from the 
NIH AIDS Research and Reference Reagent Program; Lane 4 concentrated nickel affinity 
chromatography purified HIV-1 IN. 
  
 
Figure 3.12: Western blot analysis confirming expression of recombinant PogZ. Lane 1, 
Super Western C marker (Bio-Rad, USA); Lane 2 concentrated protein following size 
exclusion chromatography; Lane 3, negative control fraction from size exclusion 
chromatography. 
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3.1.3 Modification of purified recombinant proteins 
3.2.3.1 6XHIS tag cleavage 
Thrombin cleavage was performed on both subtype B and subtype C HIV-1 IN for 
use in the AlphaScreen assay. Fractions containing the cleaved HIV-1 IN and 
uncleaved samples were analysed on an SDS-PAGE gel (Figure 3.13), and 
cleavage of the 6XHIS tag was confirmed by the absence of bands in the cleaved 
samples by Western blot analysis (Figure 3.14). 
  
 
Figure 3.13: SDS PAGE gel following thrombin cleavage of recombinant HIV-1 IN to 
remove the 6xHIS tag. Lane 1, precision plus protein molecular weight marker (Bio-Rad, 
USA); Lane 2, uncleaved HIV-1 IN subtype B; Lane 3, thrombin cleaved HIV-1 subtype B 
IN; Lane 4, uncleaved HIV-1 subtype C IN; Lane 5, thrombin cleaved HIV-1 subtype C IN.  
Figure 3.13 indicates an SDS PAGE gel of HIV-1 IN samples before undergoing 
thrombin cleavage and after thrombin cleavage. The removal of the  HIS tag from 
the HIV-1 IN was needed to prevent cross interaction with the AlphaScreen 
acceptor beads as both LEDGF/p75 and HIV-1 IN contained a HIS tag. Lane 2 
contains an uncleaved HIV-1 IN subtype B sample and lane 3 contains the 
sample after thrombin cleavage. A slight shift in migration on the gel can be seen 
between the uncleaved and cleaved samples, thus suggesting successful 
cleavage of the HIS tag. Lane 4 contains uncleaved HIV-1 IN subtype C and lane 
5 contains cleaved HIV-1 IN subtype C. Also suggesting successful cleavage as 
indicated by the slight shift in migration. 
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Figure 3.14: Western blot analysis of HIV-1 subtype B and C IN following thrombin 
cleavage of the 6XHIS tag. Lane 1, Super Western C marker (Bio-Rad, USA); Lane 2, 
HIV-1 subtype B IN 6xHIS tagged protein; Lane 3, cleaved HIV-1 subtype B IN; Lane 4, 
HIV-1 subtype C IN 6XHIS tagged protein; Lane 5, cleaved HIV-1 subtype C IN. 
 
The SDS PAGE shown in Figure 3.13 was transferred to a PVDF membrane and 
a Western blot was conducted. A primary antibody of anti-HIS was used for first 
incubation. This would then indicate the presence of a HIS tag on the uncleaved 
HIV-1 and the absence of a HIS tag on the cleaved protein.  
 
3.3.3.1 Biotinylation of recombinant proteins 
Biotinylation of HIV-1 IN subtype B and PogZ was needed for use in the non DNA 
AlphaScreen. Following biotinylation of uncleaved HIV-1 IN subtype B and PogZ, 
proteins were bound to a streptavidin coated plate, and aspirate containing any 
unbound protein was removed. Absorbance readings of the removed aspirate, as 
compared to a control buffer (containing no biotinylated protein) confirmed that 
the HIV-1 IN and PogZ were successfully biotinylated (results not shown). 
Overall, the above results confirmed that HIV-1 IN, LEDGF/p75, and PogZ were 
all successfully expressed, purified and modified (where appropriate), for use in 
subsequent biochemical/biological assays. 
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3.2 Theoretical, biochemical and biological screening of 
test compounds 
 
3.2.1 Theoretical screening of test compounds for HIV-1 IN-
LEDGF/p75 inhibition 
 
3.2.1.1 Molecular modelling of NCC collection 
HIV-1 IN-LEDGF/p75 complex (PDB2B4J) was prepared by the removal of the 
LEDGF/p75 and analysed to determine the location of the LEDGF/p75 binding 
sites on the IN molecules. Four possible sites were identified as seen by yellow 
spheres in Figure 3.15. With further model optimisation, two of the four residues 
were confirmed as LEDGF/p75 binding sites (Figure 3.16).  
 
Figure 3.15: Space filled model of prepared HIV-1 IN-LEDGF/p75 complex with 
LEDGF/p75 removed (PDB2B4J) displaying four possible LEDGF/p75 interaction sites 
indicated by yellow spheres. 
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Figure 3.16: Space filled model of the prepared HIV-1 IN-LEDGF/p75 complex (PDB 
2B4J) with the LEDGF/p75 removed showing the two confirmed LEDGF/p75 binding sites 
(arrows). 
 
To ensure the model was accurate, it was trained using known HIV-1 IN-
LEDGF/p75 inhibitors. A Boehringer ligand file was created based on data from 
Simoneau et al. including the IC50, EC50, CC50 and KD provided (Simoneau et al., 
2011), and used to validate the accuracy of the model. Of the various scoring 
functions utilised, the best fit scoring of the Boehringer compounds was seen to 
be Jain score as well as the LibDockScore.  
 
Once the accuracy was confirmed, the NCC-202 files were obtained from the NIH 
Clinical Collection and prepared for docking. The entire NCC-202 library was 
screened through the model and docking scores and energies were recorded. 
The best one thousand Jain and LibDock scoring compounds (including 
tautomers of the compounds) were further subjected to CDOCKER docking and 
In-Situ-Ligand-Minimisation. Overall, the top one thousand scoring compounds 
were a combination of only 12 compounds in different tautomer structures.  
 
The 12 compounds included prednisolone, quinidine hydrochloride, cefazolin A, 
naloxone, budesonide, amninocide, moban, methyl prednisolone, duanorubicin, 
naltrexone hydrochloride, betamethasone, and lovastatin. Because lovastatin 
was one of the 12 top scoring compounds, a further three statin compounds 
(pravastatin, simvastatin and mevastatin) were selected based on structural 
similarities to lovastatin, two derivatives (for lovastatin and pravastatin), as well 
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as atorvastatin. CX05168, a known HIV-1 IN-LEDGF/p75 inhibitor, and 
raltegravir, a known HIV-1 IN inhibitor, were included as positive controls. All 
structures of the 20 compounds selected for further screening are shown in Table 
3.1. 
 
Table 3.1: Chemical structures of the 20 selected compounds for theoretical, 
biochemical and biological screening. 
Prednisolone 
 
Quinidine hydrochloride 
 
Cefazolin A 
 
Naloxone 
 
Budesonide 
 
 
Amninocide 
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Moban 
 
 
Methyl prednisolone 
 
Daunorubicin
 
 
CPD000058767 
 
Betamethasone 
 
CX05168 
 
Lovastatin 
 
Lovastatin Acid 
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Pravastatin 
 
Pravastatin Lactone 
 
Simvastatin 
 
Mevastatin 
 
Atorvastatin 
 
Raltegravir 
 
 
3.2.1.2 Theoretical analysis of all compounds used in this study 
The 20 selected compounds were analysed in Osiris property explorer to 
evaluate their theoretical properties, including predictive analysis of compound 
lipophilicity, aqueous solubility, toxicity, drug likeness and drug score. Osiris 
property explorer also predicts if a compound will be a mutagen, turmorigen or an 
irritant. The data can be seen in Table 3.2 for the NCC compounds and Table 3.3 
for statins.  
 
Overall, of the twenty compounds screened only one (naloxone) was found to be 
an irritant, 38 % were lipophilic and 47 % were hydrophilic. Three statins were 
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found to be highly lipophilic. Solubility scores found that a total of 48 % of 
compounds had a solubility of less than -4 and all statins with the exception of 
pravastatin were found to be below -4.  
 
Table 3.2: Osiris molecular property explorer data for the 12 NCC-202 
compounds selected and 2 control compounds, showing lipophilicity (cLogP), 
solubility (LogS), molecular weight, drug likeness and drug score for each 
compound. 
Compound name cLogP LogS M.W. g/mol Drug-likeness Drug score Mutagenic Tumorigenic Irritant R.E
Raltegravir -1.05 -1.18 444 5.95 0.81
CX05168 5.68 -6.4 353 -2.05 0.21
Prednisolone 1.4 -2.96 360 4.1 0.85
Quinidine hydrochloride 2.84 -3.1 324 1.09 0.73
CefazolinA -0.77 -2.12 454 12.25 0.79
Noloxone 0.6 -2.38 329 1.29 0.65
Budisonide 2.15 -3.82 430 1.7 0.67
Amninocide 2.77 -4.7 502 1.8 0.52
Moban 1.84 -2.16 276 1.58 0.84
Methyl Prednisolone 1.59 -3.12 374 4.17 0.83
Daunorubicin 1.43 -5.01 527 6.72 0.52
CPD000058767 1.81 -3.19 341 4.67 0.85
Betamethazone 1.64 -3.25 392 3.18 0.8
Lovastatin 4.28 -4.54 404 1.65 0.54  
 
 
Table 3.3: Osiris molecular property explorer data for the seven statin 
compounds selected, showing lipophilicity (cLogP), solubility (LogS), molecular 
weight, drug likeness and drug score for each compound.  
Compound name cLogP LogS M.W. g/mol Drug-likeness Drug score MutagenicTumorigenicIrritant R.E
Lovastatin 4.28 -4.54 404 1.65 0.54
Pravastatin 3.07 -3.53 424 3.14 0.71
Simvastatin 4.79 -4.75 418 0.67 0.43
Atorvastatin 5.55 -6.92 558 1.03 0.22
Lovastatin acid 4.09 -4.09 422 3.25 0.62
Prevastatin lactone 3.89 -4.53 418 1.37 0.55
Mevastatin 4.08 -4.41 390 0.58 0.52  
 
 
 
 
 
No effect 
Negative effect 
No effect 
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The results for the Lipinski rule of five predictions of oral bioavailability of the 20 
selected compounds are shown in Table 3.4 for the NCC library and Table 3.5 for 
statins.  
 
Table 3.4: Lipinski rule of 5 for the 12 NCC-202 compounds selected for 
screening including 2 positive controls used, indicating adherence or aversion to 
the rules and a final score. 
Compound name Rule 1 Rule 2 Rule 3 Rule 4 Score
Raltegravir √ √ √ √ 4∕4
CX05168 √ √ √ X 3∕4
Prednisolone √ √ √ √ 4∕4
Quinidine hydrochloridd √ √ √ √ 4∕4
CefazolinA X √ √ √ 3∕4
Noloxone √ √ √ √ 4∕4
Budisonide √ √ √ √ 4∕4
Amninocide √ √ X √ 3∕4
Moban √ √ √ √ 4∕4
Methyl Prednisolone √ √ √ √ 4∕4
Daunorubicin X √ X √ 2∕4
CPD000058767 √ √ √ √ 4∕4
Betamethazone √ √ √ √ 4∕4
Lovastatin √ √ √ √ 4∕4  
Rule 1: Not more than 5 hydrogen bond acceptors 
Rule 2: Not more than 10 hydrogen bond donors 
Rule 3: A molecular weight under 500 g/mol 
Rule 4: A partition coefficient log P of less than 5 
X does not adhere to rule 
√ adheres to the rule 
Score: Lipinski’s rule of 5 score out of 4 
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Table 3.5: Lipinski’s rule of five for the seven statins selected for screening, 
indicating adherence or aversion to the rules and a final score. 
Compound name Rule 1 Rule 2 Rule 3 Rule 4 Score
Lovastatin √ √ √ √ 4∕4
Pravastatin √ √ √ √ 4∕4
Simvastatin √ √ √ √ 4∕4
Atorvastatin √ √ X X 2∕4
Lovastatin acid √ √ √ √ 4∕4
Prevastatin lactone √ √ √ √ 4∕4
Mevastatin √ √ √ √ 4∕4  
Rule 1: Not more than 5 hydrogen bond acceptors 
Rule 2: Not more than 10 hydrogen bond donors 
Rule 3: A molecular weight under 500 g/mol 
Rule 4: A partition coefficient log P of less than 5 
X does not adhere to rule 
√ adheres to the rule 
Score: Lipinski’s rule of 5 score out of 4 
 
Of the 20 compounds selected, all but three (amninocide, daunorubicin and 
atorvastatin) were within the acceptable parameters for molecular weight. 
Overall, 76 % abided by all four of the Lipinski rule of five with 14 % failing one 
parameter and 9.5 % failing two parameters. Two compounds, CX05168 and 
atorvastatin, were found to be above the acceptable lipophilicity score of five (rule 
4).  
 
A summary of all properties for statins (excluding the two derivatives) using 
Accelrys Discovery StudioTM, Chem Spider and Osiris molecular property 
explorer is shown in Table 3.6. In addition, Accelrys Discovery StudioTM and 
Osiris properties explorer ADMET screening data was obtained/ amalgamated for 
all NCC compounds (Table 3.7). This data was subsequently used to validate 
results from the biological testing.  
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Table 3.6: Property analysis of statins 
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Table 3.6 describes the property of analysis of statins studied in this research. 
Lovastatin, atorvastatin, simvastatin and mevastatin were similar in lipophilicity 
and were found to be more lipophilic than pravastatin and fluvastatin. There was 
no direct relationship between solubility and lipophilicity, with pravastatin being 
the most soluble and fluvastatin being the least soluble. Lovastatin and 
simvastatin had no physiological charge whereas the remaining statins were 
seen to be negatively physiological conditions.  
 
Table 3.7: Accelrys Discovery StudioTM ADMET screening of compounds 
predicting molecular weight, acceptor and donor hydrogen atoms, rotatable 
bonds, solubility and lipophilicity (AlogP). 
Compound name Molecular weight Aceptor Donor Rotatable bonds Solubility AlogP
Raltegravir 444.416 7 3 6 -2.193 -0.291
CX05168 353 2 1 5 -7.082 6.446
Prednisolone 360.452 5 3 2 -2.96 1.26
Quinidine hydrochloridd 324.424 4 1 4 -3.1 2.733
CefazolinA 476.479 11 1 7 -2.12 -2.807
Noloxone 363.842 5 2 2 -2.88 1.835
Budisonide 430.543 6 2 4 -3.82 2.198
Amninocide 502.573 7 1 4 -4.7 2.47
Moban 312.841 3 1 3 -2.15 2.522
Methyl Prednisolone 374.479 5 3 2 -3.12 1.512
Daunorubicin 527.53 11 5 4 -5.01 0.628
CPD000058767 377.869 5 2 2 -3.19 2.039
Betamethazone 392.469 5 3 2 -3.25 1.708
Lovastatin 404.549 5 1 7 -4.59 4.218
Pravastatin 424.528 7 4 11 -2.107 2.156
Simvastatin 418.566 5 1 7 -5.29 4.634
Atorvastatin 558.64 5 4 12 -5.091 5.555
Lovastatin acid 422.555 6 3 11 -3.332 3.634
Prevastatin lactone 406.512 6 2 7 -3.36 2.74
Mevastatin 390.513 5 1 7 -4.577 3.966  
Table 3.7 displays the theoretical ADMET data for all compounds studied in this 
research. ADMET refers to the adsorption, distribution, metabolism excretion and 
toxicity of a compound. The tolerability of a drug can be predicted with use of 
these parameters. Amninocide, daunorubicin and atorvastatin all have molecular 
masses exceeding 500 g/mol. CX05168, lovastatin, simvastatin and atorvastatin 
were seen to be lipophilic and were subsequently seen to be the compounds with 
low solubility scores. 
  
3.2.1.3 Preparation of compounds 
The chemical structure of the extracted lovastatin, pravastatin, simvastatin, 
atorvastatin, synthesized lovastatin acid and pravastatin lactone, and purchased 
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mevastatin was analysed by NMR and mass spectroscopy and was found to be 
above 95 % pure in all cases (results not shown). In the case of lovastatin acid, 
the yield was 58 % showing a loss of 42 % from starting material. Pravastatin 
lactone also displayed a loss in starting material of 56 % leaving a yield of 44 %. 
The schematic representation of the hydrolysis reaction for lovastatin acid can be 
seen in Figure 3.17 and the condensation reaction for pravastatin lactone can be 
seen in Figure 3.18. Lovastatin was hydrolysed by the addition of 0.1 M NaOH 
resulting in the closed lactone ring opening as seen in Figure 3.17. Pravastatin 
was condensed by the addition of triflouroacetic acid thereby forcing the open 
chain closed into the lactone form as seen in Figure 3.18. 
 
Figure 3.17: Schematic representation of the hydrolysis reaction of lovastatin to 
lovastatin acid by the addition of 0.1 M sodium hydroxide (NaOH). The closed lactone 
ring of lovastatin is forced open to form the β hydroxyl acid chain. 
 
Figure 3.18: Schematic representation of the condensation reaction of pravastatin to 
pravastatin lactone by the addition of trifluoroacetic acid. The open β hydroxyl acid chain 
is condensed to a closed lactone ring. 
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3.2.2 Biochemical and biological screening on HIV-1 IN-
LEDGF/p75 inhibitors 
 
3.2.2.1 Evaluation of the HIV-1 IN-LEDGF/p75 interaction by size exclusion 
chromatography 
The standard curve generated for calibration of size exclusion chromatography is 
shown in Figure 3.19. Both high molecular weight and low molecular weight 
markers were loaded onto the equilibrated Superdex 200 column and allowed to 
elute at 0.5 ml/min. Blue dextran was used to determine the void volume. The 
Kav for each protein was calculated and plotted against its known molecular 
weight and a standard curve was obtained. The standard curve then allows the 
calculation of the molecular mass of unknown proteins and protein complexes. 
The elution profile of the HIV-1 IN-LEDGF/p75 complex showed minor peaks at 
50 ml, 55 ml, 70 ml, 82.5 ml, 100 ml and a major peak at 115 ml (Figure 3.20). 
 
Figure 3.19: Standard curve drawn from the elution of protein standards on the size 
exclusion column, showing the calculated partition co-efficient (Kav) for each protein 
plotted against the log of the molecular weight (LogMr). 
 
Aprotinin 
RNaseA 
Carbonic anhydrase 
Ovalbumin 
Conalbumin 
Aldolase 
Ferritin 
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Figure 3.20: Size exclusion elution profile of HIV-1 IN-LEDGF/p75 complex and variants 
thereof. Arrows indicate the fractions used in subsequent analyses.  
 
HIV-1 IN and LEDGF/p75 were allowed to incubate at room temperature and 
loaded onto the Superdex 200. The column was run at 0.5 µl/ml. The eluted 
peaks seen in Figure 3.20 were analysed using the standard curve seen in Figure 
3.19, proteins eluted at sizes of 357026.0 kDa, 221368.9 kDa, 52767.5 kDa, 
15973.8 kDa, 2998.2 kDa and 714.7 kDa. The peaks at 50 ml, 55 ml and 75 ml 
corresponding to the  357026.0 kDa , 221368.9 kDa and 52767.0 kDa peaks, 
respectively were run on an SDS-PAGE reducing gel to confirm the presence of 
both HIV-1 IN and LEDGF/p75 (Figure 3.21). Lanes 2 and 3 corresponding to the 
50 ml peak contained a protein at 75 kDa and a protein at 32 kDa. Lanes 4 and 5 
corresponding to the 55 ml peak similarly contained a protein at 75 kDa and 32 
kDa. Lane 6 and 7 corresponding to the 75 ml peak only contained a protein at 
32 kDa. 
Western blot analysis, seen in Figure 22, was conducted using an anti-HIS 
primary antibody thereby confirming the HIV-1 IN-LEDGF/p75 complex (minimum 
150 kDa), unbound IN dimers and monomers (50 kDa and 32 kDa, respectively), 
and degradation products (25 kDa) (Figure 3.22). The absence of unbound 
LEDGF/p75 implies it was all bound when generating the IN-LEDGF/p75 
complex.  
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Figure 3.21: SDS PAGE reducing gel displaying peaks of possible interacting HIV-1 IN 
and LEDGF/p75. Lane 1, precision plus protein molecular weight marker (Bio-Rad, USA); 
Lanes 2 and 3, fractions from the 50ml peak, Lanes 4 and 5, fractions from the 55 ml 
peak and lanes 6 and 7, fractions from the peak at 75 ml. Molecular weights (in kDa) are 
indicated on the left. The arrows indicate LEDGF/p75 (75 kDa) and HIV-1 IN (32 kDa).   
 
 
Figure 3.22: Western blot showing the interaction of HIV-1 IN-LEDGF/p75. Lane 1, Super 
Western C marker (Bio-Rad, USA); Lane 2, interacting proteins of LEDGF/p75 and HIV-1 
IN. 
 
The controls of LEDGF/p75 and HIV-1 IN through Western blot analysis can be 
seen in Figure 3.10 and Figure 3.11 respectively. 
250kDa 
150kDa 
100kDa 
75kDa 
 
50kDa 
 
 
37kDa 
 
 
25kDa 
20kDa 
 
 
15kDa 
10kDa 
1       2 
 
250kDa 
 
150kDa 
 
100kDa 
 
75kDa 
 
50kDa 
 
37kDa 
 
 
25kDa 
20kDa 
15kDa 
10kDa 
 1           2            3           4           5            6          7         
150kDa 
50kDa 
32kDa 
25kDa 
Results 
77 
 
3.2.2.2 Evaluation of compound activity 
The AlphaScreen assay was optimised as explained previously with DNA present 
in the assay. The assay was initially developed using the known HIV-1 IN-
LEDGF/p75 inhibitor CX05168 in a 100 µl final volume assay on Opti-plates with 
subtype B HIV-1 IN. Once the assay was functional and an IC50 value was 
obtained for the control compound, the assay was scaled down to a 50 µl final 
volume. IC50 values were repeated for CX05168 to ensure the 50 µl assay was 
working accurately. A p-value of 0.83 was found showing no statistical difference 
between the CX05168 IC50 obtained in the 100 µl final volume assay in 
comparison with the scaled down 50 µl final assay volume.  
 
Once the 50 µl AlphaScreen assay was optimized, all 20 compounds were tested 
(Table 3.8 for the NCC compound and Table 3.9 for the statins). A total of 8 test 
compounds (prednisolone, naloxone, budesonide, moban, amninocide, 
lovastatin, CX05168 and atorvastatin) showed inhibition of above 50 % at 100 
µM. Screening all 20 compounds in the AlphaScreen assay using subtype C HIV-
1 IN instead of subtype B HIV-1 IN showed no statistical difference.  
 
Compounds were then run in the HIV-1 IN-LEDGF/p75 AlphaScreen without DNA 
to determine if the presence of DNA had any effect on the results. A statistically 
significant difference was seen for compounds daunorubicin and pravastatin 
lactone. In the case of daunorubicin, a p-value of 0.044 was seen when 
comparing the AlphaScreen results with the LEDGF/p75-IN-DNA assay. A p-
value of 0.002 was seen in pravastatin lactone tests between HIV-1 IN-
LEDGF/p75 and LEDGF/p75-IN-DNA assays. No other statistically significant 
differences could be seen (Tables 3.8 and 3.9). Graphic illustration of the data 
found in Tables 3.8 and 3.9 can be seen in Figure 3.23 and 3.24, respectively. 
 
The LEDGF/p75-IN-DNA AlphaScreen assay was concurrently run with PogZ 
replacing HIV-1 IN, and confirmed that all compounds were interacting with HIV-1 
IN and not LEDGF/p75 (results not shown).  
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Table 3.8: Comparison of inhibition results obtained for 13 compounds by 
subtype B HIV-1 IN-LEDGF/p75 and LEDGF/p75-IN-DNA AlphaScreen assay.  
Subtype C HIV-1 IN was also tested in the LEDGF/p75-IN-DNA AlphaScreen 
assay. 
Compound Average Standard Deviation Average Standard Deviation Average Standard Deviation
Prednisolone 46.93 2.75 49.03 0.11 44.09 1.21
Quinidine hydrochloride 30.28 4.11 31.71 5.40 33.26 2.79
Cefazolin A 33.68 7.08 37.15 2.80 31.46 2.05
Noloxone 53.51 2.29 53.67 5.69 52.35 3.00
Budisonide 53.91 3.08 58.95 9.03 51.42 1.85
Moban 51.62 0.88 53.79 1.52 52.80 5.77
Amninocide 53.63 1.72 54.76 6.78 53.02 2.02
Lovastatin  75.51 6.89 72.69 6.29 71.72 1.43
Methyl prednisolone 30.35 1.27 30.48 5.27 30.31 1.64
Daunorubicin 73.70 1.14 104.15 0.49 101.32 1.19
Betamethazone 30.81 1.57 32.97 6.97 30.75 2.06
Naltrexone hydrochloride 35.48 3.05 37.88 4.24 34.18 4.71
CX05168 91.37 6.85 85.76 2.96 88.00 1.30
LEDGF-IN LEDGF-IN Subtype C with DNALEDGF-IN Subtype B with DNA
 
 
Figure 3.23: Graphic illustration of the data set in Table 3.8, showing the comparison of 
inhibition from the compounds between the  HIV-1 IN-LEDGF/p75 interaction alone, the 
HIV-1 IN subtype B-LEDGF/p75 assay with DNA and the HIV-1 IN subtype C-LEDGF/p75 
assay with DNA. 
Figure 3.23 visually shows clear inhibition for lovastatin, daunorubicin and 
CX05168. 
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Table 3.9: Comparison of inhibition results obtained for statins by subtype B HIV-
1 IN-LEDGF/p75 and LEDGF/p75-IN-DNA AlphaScreen assay. Subtype C HIV-1 
IN was also tested in the LEDGF/p75-IN-DNA AlphaScreen assay. 
Compound Average Standard Deviation Average Standard Deviation Average Standard Deviation
Lovastatin  75.51 6.89 72.69 6.29 71.72 1.43
Prevastatin Lactone 25.77 5.53 48.52 1.13 48.30 0.96
Simvastatin 28.78 0.70 26.59 0.92 26.15 4.04
Pravastatin 8.55 3.22 3.21 3.70 8.07 1.59
Atorvastatin 54.26 2.03 54.76 1.70 52.38 1.95
Lovastatin Acid 42.48 1.69 34.24 3.10 41.25 1.78
Mevastatin 13.25 3.66 13.87 1.89 14.75 4.15
LEDGF-IN LEDGF-IN Subtype B with DNA LEDGF-IN Subtype C with DNA
 
 
Figure 3. 24: Graphic representation of data points shown in Table 3.9, showing the 
inhibition results for statin compounds tested between the  HIV-1 IN-LEDGF/p75 
interaction alone, the HIV-1 IN subtype B- LEDGF/p75 assay with DNA and the HIV-1 IN 
subtype C-LEDGF/p75 assay with DNA. 
Figure 3.24 illustrated the inhibition results for statins between the AlphaScreen 
assays. Clear inhibition can be seen for lovastatin, pravastatin lactone, 
atorvastatin and lovastatin acid. 
Eight compounds displayed over 50 % inhibition at a single dose of 100 µM 
(Table 3.10), and were subjected to a dose response test to determine their IC50 
values. The IC50 curves were run for a minimum of n=6 to confirm results 
obtained. Lovastatin had the lowest IC50 of 1.97 µM. Lovastatin inhibition dropped 
from 75.51 % down to 42.28 % when the lactone ring was opened to form 
lovastatin acid. Pravastatin lactone inhibition dropped from 25.77 % to 8.055 % 
when in open chain form. Pravastatin lactone differs from lovastatin in a hydroxyl 
group.  Simvastatin inhibition was seen to be 28.78 % and contains an extra 
methyl group attached to the butyryl group found on lovastatin. Mevastatin 
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inhibition was 13.25 % and lacks a functional group on the naphthalene structure. 
A representative IC50 curve of the control inhibitor, CX05168 can be seen in 
Figure 3.26. All compounds where the IC50 was determined were plotted on the 
same graph to show differences in slopes (Figure 3.27). 
 
Table 3.10: IC50 (in µM) of the eight compounds initially selected for showing 
above 50% inhibition, thereby preventing the HIV-1 IN-LEDGF/p75 interaction. 
Compound IC50 (µM) 
Prednisolone 29.34 ± 0.61 
Naloxone 16.53 ± 2.18 
Budesonide 5.44 ± 0.57 
Moban 27.80 ± 1.37 
Amninocide 4.85 ± 0.76 
Lovastatin 1.97 ± 0.45 
CX05168 20.46 ± 0.76 
Atorvastatin 10.22 ± 0.80 
 
 
 
Figure 3.25: Graphic representation of data shown in Table 3.10 showing the IC50 values 
obtained in the HIV-1 IN-LEDGF/p75 AlphaScreen assay excluding DNA. The best IC50 
values were seen for lovastatin, amninocide and budesonide. 
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Figure 3.26: Representative IC50 curve of the control compound CX05168 within the 
LEDGF/p75-HIV 1 IN-DNA AlphaScreen assay. CX05168 was run in a dose response on 
the LEDGF/p75-HIV-1 IN AlphaScreen assay including DNA. The percentage inhibition 
was calculated for the experiment and was plotted against the log of the concentration. 
The IC50 was then calculated to be 20.46 ± 0.76 µM. 
 
CX05168: IC50 20.46 ± 0.76 
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Figure 3.27: IC50 curves of compounds displaying inhibition in the LEDGF/p75-IN-DNA 
AlphaScreen assay. The curves for each compound were plotted on the same graph for 
comparative purposes.  
 
Overall, because lovastatin exhibited the lowest IC50 of 1.97 µM, it was selected 
(together with structurally similar statins) for further screening. Strand transfer 
activity was conducted on all statins and CX05168 in the strand transfer assay 
(Table 3.11). Table 3.11 consists of data obtained through an ELISA based 
strand transfer inhibition assay, measured in percentage, and an ELISA based 
reverse transcriptase inhibition assay, measured in µM. The strand transfer 
ELISA assay was described in section 2.3.3.1.6. Minimal strand transfer inhibition 
was seen for lovastatin, simvastatin, lovastatin acid and mevastatin. A reduction 
of 18.54 % in inhibition of the LEDGF/p75-HIV-1 IN interaction was seen with 
pravastatin but the highest reduction was seen in CX05168 and pravastatin 
lactone. Enhanced activity was seen with atorvastatin. To ensure specificity, 
lovastatin and CX05168 were run through a reverse transcriptase assay. No 
inhibition was seen for either compound. The reverse transcriptase assay was a 
kit purchased from Roche Diagnostics and was carried out as described in 
section 2.3.3.1.7.   
Budesonide: IC50 5.44 ± 0.57 
 
Amcinonide: IC50 4.85 ± 0.76 
Prednisolone: IC50 29.34 ±0.61 
Moban: IC50 27.80 ±1.37 
Naloxone: IC50 16.53 ± 2.18 
Lovastatin: IC50 1.97 ± 0.45 
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Table 3.11: The seven statins and CX05168 positive control compound tested in 
a strand transfer assay and reverse transcriptase assay. 
Compound aStrand transfer inhibition  
± STD DEV (%) 
bReverse transcriptase 
inhibition ± STD DEV (µM) 
CX05168 31.73 ± 4.89 0.12 ± 1.09 
Lovastatin 7.82 ± 5.61 -1.85 ± 3.91 
Atorvastatin Enhanced activity ND 
Simvastatin 9.4 ± 1.2 ND 
Lovastatin acid 8.6 ± 2.81 ND 
Mevastatin 0.63 ± 14.12 ND 
Pravastatin 18.54 ± 1.02 ND 
Pravastatin lactone 31.65 ± 6.63 ND 
a
Strand transfer inhibition as calculated at single doses of 100µM represented in % with standard 
deviation(STD DEV) 
b
Reverse transcriptase activity as calculated at single doses of 100µM 
represented by % with standard deviation (STD DEV), ND- not determined. 
 
3.2.3 Solubility and permeability studies 
 
3.2.3.1 Solubility 
To determine aqueous solubility for lovastatin and CX05168, a standard curve 
was obtained for each compound. A representative curve for CX05168 can be 
seen in Figure 3.28. CX05168 was dissolved in 80:20 PBS and ACN respectively, 
the samples were allowed to dissolve overnight after which the samples were 
applied to a filter plate and filtered through by vacuum. The absorbance was read 
and plotted against the concentration to formulate a standard curve from which 
compound dissolved in PBS alone could be calculated. CX05168 was tested at 
100 µM and 200 µM and found to be soluble at these concentrations. Lovastatin 
(tested at both 100 µM and 200 µM) was soluble at 100 µM but not 200 µM, and 
solubility was reduced to 125 µM. 
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Figure 3.28: Representative standard curve for aqueous solubility of CX05168.  
 
3.2.3.2 Permeability assay 
Permeability was then tested with use of the PAMPA assay, using the standard 
curves obtained during the solubility testing. Lovastatin, lovastatin acid, 
pravastatin, pravastatin lactone and CX05168 were tested to determine 
permeability across a barrier, at physiological pH of 7.4. Lovastatin, pravastatin 
lactone and CX05168 were found to be highly permeable whereas, lovastatin 
acid and pravastatin were found to have low permeability. 
 
Table 3.12: Permeability results for compounds tested in the PAMPA assay 
Compound Mean log P ± STD DEV 
Lovastatin -4.285 ± 0.075 
Lovastatin acid -5.815 ± 0.005 
Pravastatin -6.200 ± 0.040 
Pravastatin lactone -4.760 ± 0.090 
CX05168 -4.105 ± 0.025 
Mean log P as calculated by 100 µM single dose.  
<-5.00 low permeablility,  
>-5.00 high permeability. 
 
3.2.4 Antiviral and cytotoxicity assay 
All statin compounds and CX05168 were screened in MT-4 cells for cytotoxicity 
with auranofin and raltegravir used as controls (Table 3.13). MT-4 cells were 
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incubated with compound over 5 days and MTT was then added. The 
absorbance was read and CC50 were determined for each compound. All statins 
excluding pravastatin and pravastatin lactone were found to be highly toxic to 
cells, with mevastatin being the most toxic. Pravastatin was found to have no 
toxicity at concentrations of 100 µM and pravastatin lactone only being slightly 
toxic at 59.22 µM. Lovastatin and CX05168 were also tested in PBMCs but no 
statistical difference was seen between MT-4 cells and PBMC cytotoxicity (results 
not shown). 
 
An antiviral assay was conducted with MT-4 cells (Table 3.13). The MT-4 cells 
were infected by spinoculation with HIV-1NL-43 and treated with compounds in a 
serially diluted dose response for CX05618, lovastatin, atorvastatin, mevastatin, 
pravastatin and pravastatin lactone. Notable antiviral activity was seen for all 
compounds, with the exception of pravastatin. A representative curve depicted in 
Figure 3.29 compares the antiviral activity of raltegravir, CX05168 and lovastatin. 
 
Table 3.13: Compound table indicating antiviral activity and cytotoxicity levels in 
MT-4 cells. 
Compound aEC50 Cytotoxicity (µM) 
CX05168 1.78 ± 0.28 71.15 ± 2.33 
Lovastatin 6.95 ± 0.21 5.31 ± 0.19 
Atorvastatin 23.68 ± 0.21 13.36 ± 2.38 
Simvastatin ND 12.70 ± 0.66 
Lovastatin acid ND 6.53 ± 0.77 
Mevastatin 6.70 ± 2.20 3.72 ± 0.25 
Pravastatin >100 >100 
Pravastatin lactone 29.55 ± 0.56 59.22 ± 1.66 
aEC50 correlating to antiviral activity in a dose response measures in µM 
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Figure 3.29: Comparative antiviral activity of raltegravir, CX05168 and lovastatin against 
HIV-1NL4-3 in MT-4 cells. 
The toxicity profile of lovastatin was further examined by use of the xCELLigence 
system to determine when HeLa cell death occurs. Cell index, refers to the 
number of living cells, was plotted against the time the assay was run. Cells were 
allowed to grow unhindered by compound for 24 hours after which compound 
was added in a dose response manner. Each line depicted in Figure 3.30 are 
indicative of a dose with dark green indicating the highest concentration and light 
green indicating the lowest dose. Cell death was detected as early as two hours 
after being treated with lovastatin (Figure 3.30). 
 
Raltegravir 
CX05168 
Lovastatin 
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Figure 3.30: xCELLigence graph showing HeLa cell death initiated two hours after 
addition of lovastatin. Each line denotes concentration from 3.125 µM (dark green) to 100 
µM (lime green). 
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Chapter 4: Discussion 
Discussion 
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This study describes the successful identification of compounds targeting the 
HIV-1 IN-LEDGF/p75 interaction and further evaluation of the compounds 
identified. In addition, the following recombinant proteins: LEDGF/p75, HIV-1 IN 
subtype B and PogZ were successfully expressed, purified and modified for use 
in various HIV-1 IN-LEDGF/p75 assays. 
. 
4.1 Repurposing of clinical compounds is a potential 
source of antiviral inhibitors 
In the realm of drug discovery the main reason for drug failure is toxicity and 
efficacy. Safety involves favourable toxicological and pharmacokinetic profiles, 
whereas efficacy involves the precise protein target and biological pathway that is 
used for therapeutic treatment. Marketed old drugs that have already been 
optimised for safety and efficacy in a particular indication are a possible source of 
compounds that can be redirected toward new indications. This is commonly 
referred to as drug repurposing. 
 
Computational methods, such as molecular modelling, have increased the 
amount of indications that can be investigated and thereby facilitate the 
identification of old drugs for new uses. An added benefit to repurposing drugs is 
that they have already been approved for human use, and there is no further 
need to conduct phase I and phase IIa clinical trials. Furthermore, the costs 
involved in the synthesis of the drug have already been addressed which makes 
the economic factors for repurposing attractive (Oprea et al., 2011; Sleigh and 
Barton, 2010). A disadvantage of repurposing is the level of patient compliance 
with reference to side effects. For example, side effects such as nausea 
experienced during cancer therapy is a side effected deemed acceptable to a life 
threatening condition, however this would not be considered acceptable to a 
person whose quality of life is of the utmost importance. 
 
Several clinical compound collections are available for purchase such as the 
Screen-Well® FDA Approved Drug library, the John Hopkins Clinical Compound 
Collection, the Developmental Therapeutics Program Approved Oncology Drug 
Set and the National Institute of Health Clinical Collection (NCC). The NIH 
Clinical Collection (NCC) used in this study is a well-defined library of compounds 
with a history of prior use in human clinical trials, have known safety profiles and 
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are highly drug like. Moreover, the drugs contained within this library have not 
been represented in other arrayed collections (“NCC Clinical Collection,”). 
 
4.2 Molecular modelling is a useful tool in the identification 
of inhibitors 
The Accelrys Discovery Studio 3.1 package was used for molecular modelling, 
and protein PDB code 2B4J was prepared using the CHARMM based force field 
function. The preparation included building missing loops, addition of hydrogen 
atoms, bond order assignment, and optimization of bond lengths; bond angels; 
torsion angels and non-bonded interactions. LEDGF/p75 was removed from the 
protein complex leaving the HIV-1 IN dimer protein complex. A ligand file was 
created with known HIV-1 IN-LEDGF/p75 inhibitors from Bruno Simoneau and 
co-workers which consisted of IC50, EC50, CC50 and Kd (Simoneau et al., 2011). 
This file was used to test the accuracy of the model and for validation.  
 
Once the model had been tested and found to be accurate the small molecules 
contained in the NIH Clinical Collection (NCC-202) were prepared utilizing a 
CHARMM based force field function contained in Small Molecules’ Prepare and 
Filter Ligands function to add hydrogen atoms, assign bond orders, and optimize 
bond lengths, bond angles, torsion, change ionization and generate isomers and 
tautomer’s of the ligands. Testing revealed that the top one thousand compounds 
was comprised of twelve compounds in different tautomer orientations and were 
selected for further biological screening. The twelve compounds selected for 
screening included prednisolone, quinidine hydrochloride, cefazolin A, naloxone, 
budesonide, amninocide, moban, methyl prednisolone, duanurubicin, naltrexone 
hydrochloride, betamethasone, and lovastatin. 
  
Investigation of the abovementioned drug’s mode of action revealed that there 
were five anti-inflammatory drugs, including prednisolone which is a 
corticosteroid (anti-inflammatory) used to control inflammatory conditions such as 
asthma rheumatoid arthritis and colitis; methylprednisolone, a glucocorticoid used 
to reduce inflammation; budesonide, a glucocorticoid steroidal anti-inflammatory 
used in the treatment of asthma, Crohn’s disease, and non-infectious rhinitis; 
amninocide, a topical corticosteroid for the use in skin inflammation; and lastly, 
betamethasone, an anti-inflammatory ointment used for skin irritations. Two 
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drugs are opioid antagonists, including: naloxone, used to reverse the effects of 
opioid overdose, and naltrexone hydrochloride, primarily used in treatment of 
alcohol dependence. Quinidine hydrochloride is an antiarrhythmic heart agent 
and an antimalarial schizonticide. Moban is antipsychotic medication for the 
treatment of schizophrenia. Duanorubicin is an anthracycline that is most 
commonly used to treat acute leukemias. Cefazolin A is a cephalosporin 
antibiotic used to combat bacteria. Lastly, lovastatin is an anti-lipidaemia agent.  
 
Because statins have been described to have anti HIV-1 activity (Amet et al., 
2008; del Real, 2004; Ganesan et al., 2011; Giguère and Tremblay, 2004; 
Iyengar et al., 1998; Jain and Ridker, 2005; Mazière et al., 1994; Nabatov et al., 
2007), the decision was made to perform further biochemical and biological 
testing of an additional four statins and two derivatives in addition to the above 
mentioned 12 compounds. The HIV-1 IN inhibitor, raltegravir (Summa et al., 
2008), and LEDGF/p75 inhibitor CX05168 (Christ et al., 2010) were chosen as 
positive controls.  
  
4.3 Theoretical analysis is a useful tool to predict drug 
likeness of selected inhibitors 
Additional theoretical analysis and screening were performed using Osiris 
properties explorer as well as Accelrys Discovery StudioTM. In addition, the 
Lipinski rule of five was used to assess the probability of compounds as orally 
bioavailable drugs. The selected 20 compounds were screened to gather 
information on the properties of compounds to be tested such as drug likeness 
and to identify any problems for future design of HIV-1 IN-LEDGF/p75 inhibitors.  
Osiris property explorer takes six parameters into consideration, toxicity risks, 
cLogP, aqueous solubility, molecular weight, drug likeness and overall drug 
score. The toxicity risk assessment predictor relies on a set of structural 
fragments that give rise to toxicity alerts. These fragments are known to cause 
mutagenesis, tumourgenicity, irritancy and reproductive effects. The cLogP 
predictor is the logarithm of its partition coefficient between n octanol and water 
log and is a measure of compounds hydrophobicity. The desired hydrophobicity 
of a compound is below five to ensure reasonable absorption and permeation. 
Aqueous solubility (logS) is associated with the compound absorption ability and 
distribution. A high aqueous solubility is desired for systematic transportation. 
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Molecular weight is always associated with efficacy of a drug, so optimization of 
molecular weight in drug design is always important. A high molecular weight is 
associated with decreased absorption and a reduction in reaching the target site. 
The fragment based drug likeness predictor quantifies the number of fragments 
within a compound. A positive value represents drug like qualities seen in traded 
drugs. The drug likeness score sums up all assessed parameters to judge a 
compounds overall potential to qualify as a drug (Lipinski, 2004; Lipinski et al., 
2001; “Molecular Properties Prediction - Osiris Property Explorer,"). 
 
Findings from Osiris property explorer confirmed that all 20 compounds screened 
had a positive drug likeness, which was expected as most of the compounds are 
commercially available drugs. No compounds were predicted to be mutagenic, 
tumorigenic, irritants or have reproductive effects, with the exception of naloxone 
(predicted to be an irritant). Lipinski’s rule of five predicts good oral absorption 
and drug bioavailability. The four rules include: not more than five H bond donors, 
not more than ten H bond acceptors, a molecular weight of not more than 500 
g/mol and a logP of less than five. Utilizing the RO5 a score of two out of four 
would indicate that two parameters had not been met and poor absorption or 
permeability is possible. Interestingly, atorvastatin and duanorubicin had a score 
of two out of four, and CX05168, cefazolin A and amninocide had a three out of 
four score. The remainder compounds scored a perfect four out of four. From 
these results it was seen that 10 % of the compounds were predicted to have 
poor absorption and permeability.  
 
Overall, the molecular modelling and screening allowed for the identification of 12 
compounds as potential inhibitors of the HIV-1 IN-LEDGF/p75 interaction, and 
further theoretical screening of these compounds, four additional statins and two 
derivatives, raltegravir and CX05618 confirmed their drug likeness and thus 
warranted further biochemical and biological characterization for inhibition of HIV-
1 IN-LEDGF/p75. 
 
4.4 Effective recombinant protein production and 
modification for experimental use 
The production of sufficient high yields and high purity recombinant protein was 
required for experimental use during the course of the project. Optimised 
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protocols were available for recombinant subtype B HIV-1 IN production (Jenkins 
et al., 1996) however, optimisation was needed for the expression and 
purification of recombinant LEDGF/p75 and PogZ. All proteins were expressed in 
E. cloni BL21 (DE3) (pLysS) as these cells optimally express high levels of 
recombinant protein and are easily lysed by freeze/thaw cycles. In the E. cloni 
BL21 (DE3) cells, the T7 polymerase gene is under the control of the lacUV5 
promoter which can never be fully turned off, and this results in the synthesis of 
some T7 polymerase (Studier and Moffatt, 1986). For this project we used pLysS 
instead of pLysE as it expresses low levels of the phage T7 lysozyme protein 
which are low enough that when the T7 polymerase gene is turned on normal 
expression of the target gene is observed. The lysozyme attaches to and inhibits 
the T7 RNA polymerase thereby inhibiting the polymerase activity (Studier and 
Moffatt, 1986). A concentration of 1 mM IPTG was found to be the optimum 
induction concentration throughout all the expression studies. Furthermore, the 
addition of glucose was tested to see if it aided in the prevention of protein 
expression prior to induction (Grossman et al., 1998), however there was no 
notable difference to justify the use of glucose in further expression studies. 
 
The LEDGF/p75 expression protocol was modified from the protocol used by 
Vandegraaff and co-workers (Vandegraaff et al., 2006). Bacterial cells were 
grown until an optical density of 0.8-0.9, as compared to 0.6 recommended by 
most protocols. This allows bacterial cells to grow in abundance before induction, 
and requiring only a maximum of three hours incubation post-induction for 
optimal recombinant protein expression. The culture temperature was also 
altered from the normal 37°C down to 32°C before induction and further dropped 
to 28°C post induction to reduce protein degradation. This resulted in high 
expression of intact recombinant LEDGF/p75 protein (Miroux and Walker, 1996; 
Saïda et al., 2006; Vandegraaff et al., 2006). Affinity chromatography was used 
as the primary LEDGF/p75 purification step, followed by cation exchange 
chromatography to separate proteins based on their charge. Negatively charged 
proteins are washed through the column and positively charged proteins remain 
bound tightly. The negatively charged proteins are then eluted with use of a salt 
gradient that competes with the protein for column attachment (Marinsky et al., 
1973). LEDGF/p75 has a pI of 9.15 and therefore a cation exchange column was 
used with buffers at pH7.6. Size exclusion chromatography was used as the final 
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purification step where large proteins were eluted first and small proteins that 
were caught in the spaces between beads were eluted last (Lathe and Ruthven, 
1956). The final column allowed for purification to levels of approximately 95% 
purity (Figure 3.7), and the identity of purified recombinant LEDGF/p75 (75 kDa) 
was confirmed by Western blot analysis (Figure 3.10). 
  
The optimum parameters for subtype B HIV-1 IN soluble protein expression and 
purification have been previously optimised within our laboratory and these 
methodologies were successfully implemented in this study to purify subtype B 
HIV-1 IN (Figures 3.8 and Figure 3.11). The presence of additional bands in 
Figure 3.11 is a known phenomenon that occurs due to the antiserum having a 
degree of non-specificity (Pradidarcheep et al., 2008). In some instances, the 
6XHIS tag on both Subtype B and C HIV-1 IN was cleaved to prevent HV-1 IN 
interacting with nickel chelating beads, since the AlphaScreen assay contained a 
nickel chelating bead to bind to LEDGF/p75. Thrombin cleaves the 6XHIS tag by 
recognising the consensus sequence Leu-Val-Pro-Arg-Gly-Ser and cleaves the 
peptide bond between Arg and Gly. This sequence is used by many vector 
systems encoding a protease cleavage site to allow the removal of an upstream 
domain (Jenny et al., 2003). In the case of subtype B HIV-1 IN, cleavage 
occurred with no aggregation of protein, since the protein was soluble. Usually, 
HIV-1 IN has a low solubility and tends to aggregate. Jenkins et al used site 
directed mutagenesis on subtype B HIV-1 IN and replaced the lysine on position 
185 with phenylalanine which resulted in a highly soluble HIV-1 IN product 
(Jenkins et al., 1995), and this soluble subtype B HIV-1 IN was used in this study. 
However, the subtype C HIV-1 IN was wildtype (wt), and therefore a vast amount 
of aggregation occurred. For this reason, subtype B HIV-1 IN was incubated at 
room temperature and subtype C HIV-1 IN was incubated at 4°C to reduce the 
amount of aggregation. A minor change in migration can be seen in Figure 3.13 
between uncleaved and cleaved HIV-1 IN for both subtype B and C, which is as 
expected due to the absence of the 6XHIS tag. Western blot analysis confirmed 
thrombin cleavage of the 6XHIS tag (Figure 3.14).  
 
PogZ is known as a 155 kDa protein, however an over expressed protein was 
detected between 90-100 kDa, as well as at 155 kDa (Figure 3.9). Confirmation 
of the expressed protein was determined by a western blot with anti-PogZ 
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primary antibody, and bands were detected at 90-100 kDa (Figure 3.12). 
According to the anti-Pogz manufacturer’s data sheet, a band at 90 kDa was 
expected. Thus, the overexpression of a 90-100 kDa protein could be attributed 
to alternative splicing variants of the same gene, resulting in expression of 
different sized proteins.  
 
To this end, protocols for the successful bacterial expression, purification to 
sufficient yield and purity, and modifications as needed for experimental use 
during the course of this project were successfully established and implemented 
for recombinant HIV-1 IN, LEDGF/p75 and PogZ. 
 
4.5 Biochemical and biological screening of test 
compounds 
Once the recombinant proteins had been expressed, purified and modified for 
use it was important to confirm that they were conformationally intact, and 
functional. This was determined by monitoring the interaction between HIV-1 IN 
and LEDGF/p75 under physiological conditions. Size exclusion markers were 
used to calibrate the size exclusion column and establish a standard curve. 
Initially, LEDGF/p75 and HIV-1 IN were eluted separately (Figure 3.6). As 
LEDGF/p75 is a large molecule with an expected molecular mass of between 66-
75 kDa, it was expected to elute in the first peak. A protein eluted at 66 kDa, and 
this fraction corresponded to LEDGF/p75, as confirmed on a non-reducing SDS 
PAGE gel. HIV-1 IN was eluted in peaks corresponding to 75 kDa, 50 kDa and 32 
kDa, and analysed on a non-reducing SDS PAGE gel. HIV-1 IN dimerises at 
room temperature under non reducing conditions, explaining the bands at 75 kDa 
and 50 kDa as dimers (or oligomers) of HIV-1 IN (Bischerour et al., 2003). 
Following establishment of the elution profiles of HIV-1 IN and LEDGF/p75, the 
subsequent HIV-1 IN-LEDGF/p75 interactions were visualised as a small peak at 
357 kDa followed by peaks at 221 kDa, 52 kDa, 16 kDa and 3 kDa (Figure 3.20). 
The unique peaks found at 357 kDa and 221 kDa were attributed to an 
interaction between HIV-1 IN and LEDGF/p75 in different formations as these 
peaks are absent in the elution profiles of the single proteins. The peak found at 
52 kDa, correlates with dimerised HIV-1 IN. From literature it is known that HIV-1 
IN needs to dimerise prior to binding with LEDGF/p75 (Christ et al., 2010; Peat et 
al., 2012). It is possible the complex required a longer incubation time to form 
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dimers and then form a complex with LEDGF/p75 as a large peak can still be 
seen in dimeric form. However, longer incubation times caused degradation of 
proteins. Bands below 52 kDa were attributed to degradation of the proteins, 
possibly due to the extended room temperature incubation for four hours. Peaks 
pertaining to 357 kDa, 221 kDa and 53 kDa were run on a reducing SDS PAGE 
gel (Figure 3.21) and confirmed the 357 kDa and 221 kDa peaks contained both 
LEDGF/p75 and HIV-1 IN, and the 52 kDa peak contained only HIV-1 IN. 
Furthermore, the HIV-1 IN-LEDGF/p75 interaction was confirmed by non-
reducing SDS-PAGE and western blot analysis, as a complex at 155 kDa (Figure 
3.22). Although the analyses presented above confirm the IN-LEDGF/p75 
interaction, size exclusion chromatograms and western blots describing these 
have not been published previously.    
An AlphaScreen that was previously described by Christ and co-workers, was 
modified to incorporate DNA for use in this project (Christ et al., 2010). A definite 
interaction on the assay was confirmed with luminescence values in the range of 
300 000 in comparison to control values of 2000-5000. At this stage the optimum 
concentration of LEDGF/p75 to HIV-1 IN was determined by means of a titration 
plate, cross titrating various concentrations from 30 nM to 1 µM LEDGF/p75 
against various concentrations of HIV-1 IN of 30 nM to 1 µM. The optimum 
concentration ratio for IN to LEDGF/p75 was 100 nM LEDGF/p75 to 300 nM HIV-
1 IN which correlated with the values obtained by Christ and co-workers. This 
concentration was chosen to minimise protein use with sufficient luminescence to 
show the interaction or the disruption thereof. The assay was then verified with 
the use of a known HIV-1 IN-LEDGF/p75 inhibitor CX05168. A final concentration 
of 100 µM CX05168 was used to show a disruption in the LEDGF/p75-HIV-1 IN-
DNA interaction, with an inhibition of 85.76 %. Subsequently, a dose response 
curve was set up ranging from 200 µM to 0.395 µM. The IC50 for CX05168 was 
found to be 19.17 ± 1.13 µM for the 50 µl final assay volume. Despite repeated 
attempts, the IC50 for CX05168 reported in the literature (1.35 µM) was never 
achieved in the LEDGF/p75-HIV-1 IN-DNA AlphaScreen assay (Christ et al., 
2010). The CX05168 compound was then tested in the HIV-1 IN-LEDGF/p75 
AlphaScreen assay (no DNA) with ten serially diluted samples from 200 µM down 
to 0.195 µM, and an IC50 of 1.33 µM was determined, as expected. The 
differences in IC50 values noted between the two assays was attributed to recent 
findings showing that CX05168 is a dual inhibitor of HIV-1 IN multimerization and 
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IN-LEDGF/p75 interaction (Le Rouzic et al., 2013). Thus, the prior addition of 
DNA in the IN-DNA-LEDGF/p75 AlphaScreen assay increasing multimerization of 
HIV-1 IN prior to LEDGF/p75 binding thus diminishes the inhibitory effect of 
CX05168.  
    
Screening of all compounds at a single dose through the LEDGF/p75-HIV-1 IN-
DNA AlphaScreen assay revealed that all compounds exhibited a degree of 
inhibition. However, only six compounds showed inhibition above 50 % 
(naloxone, budesonide, moban, amninocide, lovastatin and duanorubicin) with 
prednisolone falling just below at 49 % inhibition (n=7). Duanorubicin showed 
inhibition >100 %, and upon further inspection, it was found to be a DNA 
intercalator. The compounds’ were further screened in the LEDGF/p75-HIV-1 IN-
DNA AlphaScreen assay with subtype C HIV-1 IN, and no statistical difference 
could be seen between the results obtained with subtype B. In addition, the 
compounds were screened through the HIV-1 IN- LEDGF/p75 AlphaScreen 
assay (no DNA) at a single dose. Duanorubicin still showed an inhibition of 73.70 
%, however, due to potential toxicity concerns it was not taken forward for further 
biological experimentation. Thus, only six compounds were studies further.   
 
The IC50 values of prednisolone, naloxone, budesonide, moban, amninocide and 
lovastatin were tested in a dose response curve with ten serial dilutions from 200 
µM to 0.39 µM. Prednisolone showed an IC50 of 29.34 µM, followed by moban at 
27.80 µM, naloxone at 16.53 µM, budesonide at 5.44 µM, amninocide at 4.85 µM 
and finally 1.97 µM for lovastatin. Based on the low IC50 value obtained for 
lovastatin, the favourable theoretical profiles, and previously published literature 
on the anti HIV-1 activity of statins, it was decided to conduct further testing on 
lovastatin, and other statins with structurally similar components. Furthermore, 
lovastatin was found to specifically target the HIV-1 IN-LEDGF/p75 interaction, 
since no anti-RT or strand transfer activity was detected.  
It should be noted that the dose response curves of lovastatin and CX05168 
show differences. The slope of CX05168 reaches from 0 close to 100 % inhibition 
and follows a steep slope, indicative of a potent inhibitor and a full antagonist. By 
contrast, the slope of lovastatin is not as steep indicating a less potent inhibitor 
and only reaches 70-80 % inhibition, indicative of a partial antagonist. These 
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factors must all be considered when designing future inhibitors as it is desirable 
to have full antagonists and potent inhibitors (Shen et al., 2008).  
 
4.6 Statin class of drugs act as HIV-1 IN/LEDGF/p75 
inhibitors 
Lovastatin was identified as the “lead” HIV-1 IN-LEDGF/p75 inhibitor following 
screening of the twelve NCC-202 compounds chosen by molecular modelling. 
Overall, a 72.55 % inhibition was seen with a single dose of lovastatin on the 
AlphaScreen assay with an IC50 of 1.97 µM. Additionally, a DNA binding assay 
using cisplatin (Sigma Aldrich, USA) as a control, confirmed that lovastatin was 
not interacting with the DNA present on the assay (methods and results not 
shown). This then lead to utilizing various statin compounds with slight structural 
differences to elucidate which components contributed to the inhibitors profile. 
Atorvastatin was included as it was previously identified as a HIV-1 IN-
LEDGF/p75 inhibitor (Hu et al., 2012). Additional statins chosen for screening 
included pravastatin, mevastatin, simvastatin and two pravastatin and lovastatin 
derivatives, namely pravastatin lactone and lovastatin acid. Three statins showed 
reasonable HIV-1 IN-LEDGF/p75 inhibition; lovastatin inhibited the interaction the 
most with 72.69 % inhibition in subtype B and 71.72 % inhibition with subtype C. 
Atorvastatin followed at 54.76 % inhibition with subtype B and 52.38 % inhibition 
in subtype C. Pravastatin lactone showed reasonable inhibition at 48.52 % in 
subtype B and 48.30 % in subtype C. Other statins showed inhibition but at lower 
levels such as simvastatin at 26.59 % and 26.15 % inhibition with subtype B and 
C respectively, lovastatin acid inhibited the interaction at 34.24 % and 41.25 % 
with subtype B and C respectively and mevastatin inhibited at 13.87 % and 14.75 
% subtype B and C respectively. Other statins tested showed negligible inhibition. 
Statins structures were compared with one another to determine which structural 
components contributed to inhibition. Lovastatin was derivatised to lovastatin acid 
by the hydrolysis of the lactone ring to an open chain (Deak et al., 2002; Huang 
et al., 2010b; Önal and Sagirli, 2006). This hydrolysis reduced the inhibition from 
71.72 % to 41.25 %. Pravastatin showed little to no inhibition at 8% but once the 
open chain was condensed to pravastatin lactone (Deak et al., 2002; Önal and 
Sagirli, 2006; Tanaka and Terahara, 1982) the inhibition increased to 48.52 %. 
This indicates that the presence of the lactone form aids in the inhibitory profile. 
Pravastatin lactone and lovastatin differ by a single functional group, in the case 
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of lovastatin a methyl group is present and in pravastatin lactone the methyl 
group is replaced by a hydroxyl group on the naphthalene structure. Mevastatin 
differs from lovastatin as there is no functional group on the mevastatin as 
opposed to the methyl group on lovastatin. Mevastatin inhibited by only 13 %. 
This indicated that the methyl group in combination with the closed lactone ring is 
needed for inhibition. Simvastatin contains an additional methyl group on the 
butyrl group in comparison to lovastatin and the inhibition dropped to 23 % in 
simvastatin. Overall, from the comparison of inhibition and structure of statins it 
appears the presence of a closed lactone ring in addition to a methyl group is 
involved in the inhibitory activity noted. Interestingly, alterations in the butyryl 
group appear to have an adverse effect on inhibition. 
 
Comparison of results from the HIV-1 IN-LEDGF/p75 AlphaScreen assay, in the 
presence or absence of DNA showed no statistical differences, with the exception 
of pravastatin lactone. Inhibition in the absence of DNA showed a 22.75 % drop 
in inhibition, which was statistically significant (p=0.002), which is contrary to 
CX05168. This may be attributed to pravastatin lactone binding to/interfering with 
DNA thereby reducing the amount of HIV-1 IN in contact with the streptavidin 
donor bead thereby reducing signal detected. However, no literature could be 
found detailing the interaction of pravastatin lactone with DNA. Other possible 
factors include pH of the compound as triflouroacetic acid was used to condense 
the open chain. If the pH of the compound is extremely low it would cause the 
experimental pH to drop thereby giving inaccurate results. 
 
Aqueous solubility testing was performed on lovastatin, lovastatin acid, 
pravastatin and pravastatin lactone to determine if the structural change had an 
effect on the solubility of the compounds. Aqueous solubility of a compound is a 
concentration (mol/l) of its saturated aqueous solution which is affected by 
molecular weight and the amount of energy required to dissociate from crystalline 
structure into solution. Lovastatin was soluble at levels of ≤100 µM, whereas 
lovastatin acid was soluble up to levels of 200 µM. Pravastatin and pravastatin 
lactone were soluble to levels of 200 µM. In this instance, solubility appears 
unaffected by structural changes.    
The ability of compounds to permeate a membrane was tested for lovastatin, 
CX05168, pravastatin lactone, pravastatin, and lovastatin acid. Lovastatin, 
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CX05168 and pravastatin lactone were highly permeable, whereas pravastatin 
and lovastatin acid had low permeability with little compound crossing the 
membrane. Results of the solubility and permeability for statins reported here 
correlate with previous studies (Serajuddin et al., 1991), and confirm the 
hypothesis that the more hydrophilic a compound the less permeable a 
compound is.  
  
4.7 Antiviral activity of statins overlaps with cytotoxicity 
All statins were screened in a cell cytotoxicity assay as well as an antiviral assay. 
The EC50 for lovastatin was 6.95 ± 0.21 µM, with a CC50 of 5.31 µM in MT-4 cells 
and a CC50 of 6.50 ± 0.31 µM in PBMCs. Further testing of the cytotoxic effect of 
lovastatin on HeLa cells in the xCELLigence system showed cell death was 
initiated as early as two hours post lovastatin treatment. Thus, it was impossible 
to establish whether the compound exhibited any antiviral activity in MT-4 cells as 
a direct result of interfering with the HIV-1 IN-LEDGF/p75 interaction, or wholly 
due to cytotoxicity.  
 
Lovastatin is a well-known anti-cholesterol drug marketed and used on a daily 
basis. This raises the question of how can lovastatin be cytotoxic, yet still be used 
on a daily basis. Lovastatin is a prodrug, and, when ingested the drug undergoes 
a structural change in the stomach acid to form the active drug which is then 
absorbed (Wu and Farrelly, 2007) the closed lactone ring opens to the non toxic 
open chain when ingested and is therefore not toxic to the body. As described 
earlier, we synthesized lovastatin hydroxyl acid which is the active drug form. 
However, lovastatin acid was also highly toxic, with a CC50 of 6.53 ± 0.77 µM. 
This was possibly attributed to the open hydroxy acid chain reverting back to the 
closed formed lactone ring of lovastatin during the five days the compound was 
incubated with cells at physiological pH of 7.4. Similarly, mevastatin activity was 
attributed to cytotoxic effects, since it had an antiviral EC50 of 6.70 ± 2.20 µM but 
had a CC50 of 3.72 ± 0.25 µM. Simvastatin and lovastatin acid were not tested in 
the antiviral assay as the high toxicity of the compounds excluded the possibility 
of an accurate antiviral EC50.  
 
Pravastatin was tested in both antiviral assays and cytotoxicity assay, but 
showed no toxicity at levels of 100 µM, nor antiviral effects at the same levels. As 
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described earlier pravastatin was also condensed into the lactone form, and 
exhibited a CC50 of 59.22 ± 1.66 µM, and an EC50 of 29.55 ± 0.56 µM. An SI 
value of two implies the activity could not be completely attributed to cytotoxicity 
of the compound. SI is known as the therapeutic index and is a ratio of toxicity to 
effective dose of a compound, and the higher the SI the better this is for 
therapeutic use. An SI of two is found in some drugs such as digoxin which is a 
cardiac glucoside (Becker, 2007). However a SI of two is undesirable and would 
need constant monitoring to ensure correct circulating levels. Atorvastatin was 
also tested and was found to have a CC50 of 53.49 ± 1.03 µM and had an EC50 of 
23.68 ± 0.21 µM. This gave us an SI of 2.26. With the SI taken into consideration 
and the lack of ability to test other statins in the structural formation needed for 
antiviral activity it was determined that future studies on statins for antiviral 
activity was not conducible to effective results. 
 
Statin structures were further compared to try and decipher which structural 
components added to the cytotoxicity of the compound. The most toxic statin was 
mevastatin whose structure differs from that of lovastatin by the lack of a methyl 
group on the naphthalene structure. It was found to have a CC50 of 3.72 ± 0.25 
µM; lovastatin was found to be the next most toxic with a CC50 value of 5.31 ± 
0.19 µM. The addition of a methyl group on the naphthalene ring appears to have 
decreased the toxicity; however the effect is minimal. Simvastatin (CC50 of 12.70 
± 0.66 µM) is identical to lovastatin with an additional methyl group on the butryl 
chain. Pravastatin lactone differs from lovastatin in the replacement of the methyl 
group on the naphthalene ring by a hydroxyl group and toxicity was seen at 
levels of 59.22 ± 1.66 µM, further decreasing the toxicity. Lovastatin acid was 
found to be toxic at levels of 6.95 ± 0.21 µM but we could not guarantee the 
hydroxyl acid form as we hypothesised that the lactone ring was reforming during 
the five day incubation. Pravastatin (no toxicity at 100 µM) differs from lovastatin 
by the lactone ring, which is open in the hydroxyl acid form and the methyl group 
on the naphthalene structure which is replaced with a hydroxyl group. From these 
findings it was determined that the open hydroxyl acid form decreased the toxicity 
of a compound. Furthermore, the addition of a methyl group on the naphthalene 
reduced toxicity which was further reduced by the replacement of the methyl 
group with a hydroxyl group. The addition of a methyl group on the butyryl chain 
appeared to improve tolerance of the drug.  
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Overall, structural attributes of statins were investigated for both toxicity and 
inhibitory effects. The closed lactone ring increased the inhibition of a compound 
with the need for a functional group on the naphthalene structure. Weighing both 
toxicity and inhibitory effect in vitro we determined that the presence of a closed 
lactone ring is needed with a functional group on the naphthalene ring. However, 
combining all the results, we found that the hydroxyl group on the naphthalene 
ring made the compound too hydrophilic and prevented it from staying bound in 
the LEDGF/p75 binding pocket. 
  
From the molecular modelling, the LEDGF/p75 binding pocket was found to be 
mostly hydrophobic and therefore hydrophilic compounds would be unable to 
remain in the binding pocket. Compounds that are hydrophobic are expected to 
bind in the pocket for longer. However, if the lipophilicity of a compound is too 
high, it cannot remain in the pocket, due to the lipophilic compound repelling 
water, thereby preventing it from forming a protective barrier over the compound-
LEDGF/p75 binding site complex. A balance between lipophilicity and 
hyrdophilicity needs to be struck to allow the binding of the compound in the cleft 
and the formation of a water barrier to keep the complex in place. This 
phenomenon can partially explain the binding of statins such as lovastatin, 
pravastatin lactone, and atorvastatin, and the lack of binding of the highly 
lipophilic pravastatin.   
4.8. Conclusions and future work 
In summary, twelve potential HIV-1 IN-LEDGF/p75 inhibitors were identified by 
molecular modelling, of which six significantly interfered with the HIV-1 IN-
LEDGF/p75 interaction. The subsequent work focused on a class of compounds 
known as statins. Future work should investigate the five remaining NCC-202 
compounds identified as potential HIV-1 IN-LEDGF/p75 inhibitors.  
Statins were found to be HIV-1 IN-LEDGF/p75 inhibitors and the study of 
structurally similar statins enabled us to identify structural components 
contributing to inhibition activity and cytotoxicity. A closed lactone ring in addition 
to a methyl group had a favourable effect on inhibition; however the lactone ring 
appeared to infer toxicity. A delicate balance between the lipophilicity of a 
compound and hydrophilicity is needed for future design and/or optimization of 
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effective HIV-1 IN-LEDGF/p75 inhibitors. Statins were found to be highly toxic in 
their prodrug form which appears necessary for inhibition of the HIV-1 IN-
LEDGF/p75 interaction. The toxicity of the compounds made accurate antiviral 
levels unattainable with the exception of pravastatin lactone and atorvastatin.  
Based on the results of this study, the statin class of drugs appears to have no or 
little value as antiretroviral drugs, primarily due to toxicity concerns. Future work 
on the design of novel compounds targeting the HIV-1 IN-LEDGF/p75 interaction 
must consider the structural insights gained from this study.  
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